A Clinicopathological Study of Ovarian Tumors and

The Role of Immunohistochemical Proliferative

Marker Ki 67. by Lavanya, R
A CLINICOPATHOLOGICAL STUDY OF OVARIAN TUMORS AND THE 
ROLE OF IMMUNOHISTOCHEMICAL PROLIFERATIVE MARKER Ki 67  
 
 
 
DISSERTATION SUBMITTED FOR 
M.D BRANCH III 
(PATHOLOGY) 
 
 
 
 
 
 
 
 
 
THE TAMILNADU DR. M.G.R. MEDICAL UNIVERSITY 
CHENNAI – TAMILNADU 
MARCH – 2012 
 
 
 
 
 
 
Department of Pathology, 
Madurai Medical College and       
Government Rajaji Hospital, 
Madurai.  
 
CERTIFICATE 
 
 This is to certify that the dissertation entitled                                          
“ A CLINICOPATHOLOGICAL STUDY OF OVARIAN TUMORS AND 
THE ROLE OF IMMUNOHISTOCHEMICAL PROLIFERATIVE 
MARKER Ki 67 ” submitted by Dr. R.Lavanya to the Faculty of Pathology, 
The Tamilnadu Dr. M.G.R. Medical university, Chennai in partial fulfilment 
of the requirement for the award of M.D. Degree in Pathology is a bonafide 
work carried out by her during the period  2009 - 2011 under my direct 
supervision and guidance. 
 
Place: Madurai 
Date:  
Professor and Head,  
     Department of Pathology,  
     Madurai Medical College,  
     Madurai.  
 
  
ACKNOWLEDGEMENT 
 I express my sincere thanks to The Dean, Madurai Medical 
College, Government Rajaji Hospital, Madurai and the ethical 
committee for permitting me to carry out this study. 
 
         I wish to express my heartfelt thanks to the respected Professor                  
Dr. Usha Ravikumar, M.D., Professor and Head of the Department of 
Pathology, Madurai Medical College, Madurai for her valuable 
suggestions, constant encouragement and able guidance throughout 
this work. 
 
 I express my gratitude to all the Associate Professors, 
Dr.Meenakumari,M.D., Dr.Sivagami,M.D., Dr.Sharmila 
thilagavathy, M.D and all the Assistant Professors and Tutors for their 
valuable suggestions and guidance in this work. 
  
          I thank the Professor and Head of the department of Obstetrics 
and Gynaecology and Surgical Oncology, Government Rajaji Hospital , 
Madurai  for granting me permission to conduct this study. 
 
 I thank the entire technical staff  for teaching me the practical 
aspects of pathology with patience. 
 
 I thank all my friends in the department of pathology and in 
other departments of Madurai Medical College for their help and 
guidance. 
  
 
CONTENTS 
 
 
S.No 
 
TITLE 
 
PAGE No 
 
1 
 
INTRODUCTION 
1 
 
2 
 
AIM OF THE STUDY 
3 
 
3 
 
REVIEW OF LITERATURE 
4 
 
4 
 
MATERIAL AND METHODS 30 
 
5 
 
OBSERVATION AND RESULTS 
33 
 
6 
 
DISCUSSION 
51 
 
7 
 
SUMMARY AND CONCLUSION 
68-71 
 
 
 
ANNEXURE I – PROFORMA 
 
 
 
 
 
ANNEXURE II -  STAINING TECHNIQUES 
 
 
 
 
ANNEXURE III – WHO CLASSIFICATION OF                    
OVARIAN TUMORS 
 
 
 
 
ANNEXURE IV – ETHICAL COMMITTE APPROVAL 
 
  
ANNEXURE V- BIBLIOGRAPHY 
 
  
ANNEXURE VI- MASTER CHART 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction  
 
 
INTRODUCTION 
 
 
Like the everyform of cancer, early detection is what all about.. It can be 
prevented with testing and it can be beaten if caught early! 
                                                                                            -Rod Stewart 
        The ovarian tumors are not a single entity, but a complex wide 
spectrum of neoplasms involving a variety of histological tissues, ranging 
from epithelial tissues, connective tissues, specialized hormone secreting 
cells to germinal and embryonal cells.
40 
 
The ovary is complex in its embryology, histology, steroidogenesis 
and has potential to develop malignancy
40
. Of all the gynecologic cancers, 
the ovarian malignancies represent the greatest challenge because the ovary 
gives  rise to greater and larger variety of tumors than any other organ.A 
female’s risk at birth of having ovarian tumor sometime in her life is 6-
7%,of having ovarian cancer is almost 1.5% and dying from ovarian cancer 
is 1%
49
 
     The incidence of ovarian cancer ranks below only to the carcinoma of 
cervix.The ovarian tumors constitute about 5% of gynaecological 
admissions.  About 75% of them are benign and 25% are malignant. In 
India, ovarian tumors account for 8% of all gynecological malignancies
43
 
        Different tumors tend to involve different age groups.They occur in 
perimenopausal and postmenopausal women, infrequently in children also. 
The risk of developing ovarian tumor peaks in the fifth decade of life
88.
 The 
ovarian tumors pose a special diagnostic and management problem in the 
postmenopausal women because of their late presentation , high  risk of 
malignancy and poor prognostic  outcome and  in children pose a great 
challenge to the clinicians owing to the need of conservation of 
reproductive, endocrinal and menstrual function on one hand and malignant 
potential on the other. 
Apart from primary tumors, ovaries are frequent site for metastatic 
involvement from organs like stomach, colon and breast 
 Signs and symptoms of ovarian cancer are frequently absent or subtle 
early on , or persist  for several months before being recognized and 
diagnosed. More than 50% of patients are diagnosed in the advanced stage 
of the disease. 
              This study is undertaken to analyze the histopathological spectrum 
and clinical features  and to emphasize the importance of 
immunohistochemical markers in accurate diagnosis and to investigate the 
biological significance of Ki 67 antigen expression in benign, borderline and 
malignant ovarian tumors.  
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Aims & objectives   
 
 
AIMS AND OBJECTIVES 
 
 
1. To study the incidence of ovarian  tumors in our institution during 
2009-2011. 
 
2. To study the age related occurrence  and clinical presentation of 
various types of ovarian  tumors. 
 
3. To  classify ovarian tumors based on gross and  histopathological 
features and categorizing them into benign, borderline and malignant 
tumors. 
 
4. To apply special stains like  Reticulin, Periodic Acid Stain (PAS)  in  
selected   cases  for differentiation of tumors. 
 
5. Application of  immunohistochemical markers  in selected  cases  for 
final diagnosis. 
 
6. To analyze the role of immunohistochemical proliferative marker Ki 
67 in selected cases. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Review of literature   
 
                   REVIEW OF LITERATURE 
Historical aspects 
 A historical account of the ovary should begin with Herophilus of 
Chalcedon, a great anatomist of Alexandrian school of the fourth century  
B.C “Hemophilus must be regarded as the first anatomist to describe the 
mammalian ovaries. He called it “female testis”.  
. 
FEMALE GENITAL TRACT 
 
 
 Fig.1 
                                ANATOMY OF  OVARY 
Ovary develops from the genital ridge by 5
th
 week  of gestation and 
oogonia develops by mid gestation. 
The ovaries which are the site of oogenesis are paired organs lying on 
either side of the uterus adjacent to the lateral wall of the pelvis(Fig1)
.100
 
 During active reproductive life, ovaries measure about 4x2.5x1cm in 
dimension. The ovary is divided into cortex and medulla. Follicles in 
varying stages of maturation are found within the outer cortex
89
.These are 
numerous in  infants  and young adults, where they are estimated  to total 
about 4,00,000 but the number progressively decreases with age and follicles 
disappear by  menopause. 
105 
 With each menstrual cycle, one follicle develops into a graffian 
follicle, which is transformed into a corpus luteum following ovulation.  
         The medulla of the ovary consists a loosely arranged mesenchymal 
tissue and contains remants of both wolffian duct (rete ovarii) and small 
clusters of round to polygonal, epithelioid cells around vessels and nesves.  
The ovaries are also endocrine organs producing the hormones oestrogen 
and progesterone.  
 
HISTOLOGY 
Numerous ovarian follicles are seen in various stages  of development  
in the stroma of cortex. Primordial follicles contain the  immature small 
primary oocyte which gradually increases in size and develop into primary, 
secondary and mature follicles(Fig 2). 
 
  
 
 
 
 
 
 
 
 
Fig 2 
         Follicles with antral cavities  are called secondary follicles which 
exhibit  a granulosa cell layer, a theca interna and an outer theca 
externa.
23
The largest ovarian follicle is the mature graffian  follicle which  
ultimately ruptures and the ovum is shed from the ovary( ovulation). After 
ovulation the remaining part of the follicle undergoes changes that convert it 
into Corpus Luteum
23. 
If the ovum is not fertilized, the corpus 
luteum,degenerates into corpus albicans,and if fertilized it  persists and 
secretes progesterone . 
The series of changes that begin with the formation of an ovarian 
follicle and end with the degeneration of the Corpus Luteum constitutes the 
ovarian cycle.  
 The main function of the ovary is to produce ova to implant after 
fertilization in the endometrium, and as an endocrine gland in the 
development of secondary sexual characters . Thus the ovary is always in 
dynamic state
85.
Ovaries  serve as the main organ for maintaining the female 
fertility and at the same time, site of origin of the most complex as well as  
lethal neoplasms. 
OVARIAN CANCER 
 
Most primary ovarian neoplasms are derived from one of these components 
1.Coelomic surface epithelium covering ovary. 
2. The ovarian stroma , sex cord or both. 
3. The germ cell. 
 
CLINICAL FEATURES 
 
Signs and symptoms of ovarian cancer are frequently absent early on 
and when they exist they may be subtle
32
.Symptoms such as abdominal pain, 
mass, ascites, urinary urgency, constipation, ,abnormal vaginal bleeding, 
weight loss can  occur
4
. Functionally active ovarian tumors in young 
girls(Juvenile granulosa cell tumors) may produce precocious puberty. 
Occasionally they produce androgens, masculinizing the patient. 
DIAGNOSIS OF OVARIAN CANCER 
 
Histopathology  
 
        Histopathology is the most common diagnostic method used for the 
diagnosis of ovarian tumors. Tissue samples from ovariotomy specimens are 
fixed in 10% buffered neutral formalin and then processed. Sections made 
with the help of microtomes  are routinely stained with hematoxylin and 
eosin andthen studied microscopically in detail.. Ascitic fluid cytology is 
helpful in the diagnosis of metastasis in advanced stage of ovarian tumors. 
 
 
 SPECIAL STAINS:  
 
 The most commonly used  stains are PAS and  Reticulin stain. PAS 
stain is an extremely useful and aesthetically pleasing technique to 
differentiate mucinous carcinoma from krukenberg tumor. Mucinous 
carcinoma of ovary shows PAS positive mucin pools, and krukenberg tumor 
show intracellular PAS positivity .Reticulin stain is useful to differentiate 
granulosa cell tumor from fibrothecoma. It shows fibrils surrounding the 
nests and large aggregates of granulosa cell tumor whereas in Fibrothecoma, 
it highlights an investment of individual cells by fibrils.   
 
 
 
 
 
IMMUNOHISTOCHEMISTRY: 
 
 Diagnostic IHC markers  for epithelial ovarian tumors are Epithelial 
membrane antigen(EMA) and Cytokeratins, for sex cord stromal tumors are 
Inhibin, vimentin,calretinin,CD 99, Melan A,WT 1 and for Germ Cell 
Tumors the markers are Placental Alkaline Phosphatase (PLAP), Alpha Feto 
Protein (AFP), Human Chorionic Gonadotrophin (HCG). 
 
Role of anticytokeratin in distinguishing primary and  
secondary ovarian adenocarcinoma  
 
 Keratins are intermediate filament proteins that contribute to the 
cytoplasm of epithelial cells. Human cytokeratin have been classified 
according to their molecular weight and isoelectric  pH.20 epithelial 
cytokeratin polypeptides have been identified. Some of these have specific 
tissue distribution that can be exploited for the differential diagnosis of 
tumor. 
 
  CK7(+) / CK20 (-)   :In all primary epithelial ovarian neoplasms,
18 
 
   CK 7(-) / CK20(+)  : Secondary (metastatic ) tumors except in intestinal 
type of mucinous carcinoma of ovary.
18 
 
 
 
PROLIFERATIVE MARKERS: 
 
     The number of mitotic figures correlated with cancer stage and gradeas 
well as with their progression. Immunohistochemical  proliferative markers 
like  Ki 67 , proliferative cell nuclear antigen (PCNA)  , AgNOR count are 
used to assess mitotic activity
. 17
 The number of mitotic figures increase 
progressively from benign to malignant tumors  . 
 Ki 67 protein is a cellular marker for nuclear proliferation which is 
present in all phases  of cell cycle (G1S,G2M) and is absent in resting phase 
(G0). Ki 67 is an excellent marker to determine the growth fraction of a 
given cell population. The determination of growth fraction using Ki 67 
index is a simple method and has long been shown to have a prognostic 
value in a variety of malignancies like CNS tumors, Lymphoproliferative 
diseases, connective tissue tumors & breast tumors
69
. The fraction of Ki 67 
positive tumor cells (Ki 67 labelling index) is often correlated with clinical 
course of cancer. 
 
Tumor markers in ovarian cancer  
Tumor markers are biochemical indicators of presence of tumor. The term 
usually refers to a molecule that can be detected in plasma or other body 
fluids 
56
 
 None of the tumor markers for ovarian carcinoma is 100% specific or 
100% sensitive.   
a) Tumor markers for epithelial ovarian cancer 
           Approximately 90% of ovarian cancers are coelomic epithelial 
carcinomas and contain a coelomic epithelium related glycoprotein, 
designated Cancer Antigen 125. This can be recognized in most serous, 
endometrial, and clear cell ovarian carcinomas. 
  The other serological tumor markers for epithelial ovarian cancer include 
carcinoembryonic antigen (CEA), CA 15-3, CA 19-9, LASA (lipid 
associated safe acid) and tissue peptide antigen.  
 
 
b)Tumor markers in non-epithelial ovarian cancer:  
 
 Alphafetoprotein and human beta HCG are the best known tumor 
markers in clinical practice and aid in treatment, follow-up of ovarian germ 
cell tumors
42
.Serum placental alkaline phosphatase and lactate 
dehydrogenase are also sometimes useful as markers of dysgerminoma.   
  
FLOW CYTOMETRY 
 
 The application of flow cytometry to ovarian tumor pathology may be 
considered principally in term of measuring the ploidy status of tumor. Most 
borderline tumors are diploid & if aneuploid it indicates progression.well 
differentiated tumors are diploid whereas poorly differentiated tumors are 
aneuploid  and having worse prognosis. 
CYTOGENETICS:  
 It has been shown that p53 gene is mutated in 30-80% of ovarian 
carcinomas.  p53 overexpression is associated with increased probability of 
relapse and decreased survival. BRCA 1, and BRCA 2  are expressed  in 
hereditary tumors. Teratomas show chromosomal aberrations.  
 
REVIEW OF INDIVIDUAL OVARIAN TUMORS 
 
                      
 I) SURFACE EPITHELIAL TUMORS 
 
          In 1870,   Heinrich waldeyer  wrote a paper on epithelial ovarian 
tumors.He was among the first to suggest a histogenesis similar to that 
which is now widely accepted for the most common form of ovarian tumor. 
These tumors are derived from the epithelium that normally lines the outer 
aspect of ovary, referred to as surface coelomic or germinal epithelium and 
the adjacent ovarian stroma 
85
 
These tumors comprise 58% of all ovarian neoplasms and more than 
90% of malignant tumors. They  are classified into benign, borderline and  
malignant. Epithelial neoplasm  may occur in young women and are rare 
before menarche. This incidence increase especially after the age of 55 
years. 
 
A)SEROUS TUMORS:  
 Constitute 30% of all ovarian tumors, making them the single most 
common group. About 50-70% are benign, 10-15% are borderline, while 25-
35% are frankly malignant. About 30-50% are bilateral
16
 
Benign Serous Tumors:  
 Commonest tumor making up about ¼ th of all ovarian tumors, occurs 
between 10-60years of age, average being 45 years. Majority of them are 
unilateral and cystic. These include serous cystadenomas, serous 
cystadenofibroma, serous adenofibroma and serous surface papillomas.  
Gross:  
 Cystic, usually have a smooth pale yellow (or) gray white exterior 
with a prominent vascular pattern. It can be either unilocular or multilocular. 
They contain clear, thin serous fluid.  
Microscopy:  
 Cyst wall and papillae lined by single layer of a mixture of tall ciliated 
and non-ciliated columnar cells with elongated oval nuclei interspersed with 
a variable number of peg shaped cells and clear cells resembling the normal 
tubal epithelium. Psammoma bodies are calcific spherules , seen in 15% of 
cases
82 
 
Borderline Serous Tumors: 
    Howard  C Taylor expanded on the concept of  tumors  intermediate 
between benign & malignant. He wrote a paper on borderline ovarian 
tumors. 
     These tumors are large usually multilocular ,  bilateral in 35-40% of 
cases. Coarse papillary excrescences arise from the cyst lining 
17 
. Most 
common in fourth and fifth decades with average age of 46 years. 
   Microscopy:  
          The characteristic microscopic features of borderline serous tumors are 
Hierarchial branching papillary pattern of growth with variable cytologic 
atypia, Cellular stratification greater than 3 cells. Frank stromal invasion  
is absent,Stromal microinvasion (<3mm) is occasionally identified in a 
borderline serous tumor.
17
 
  Malignant serous tumors: 
     Occurs in mean age 56 years, bilateral–in 2/3 of cases 
82 
  Gross:  
      These are large, often bilateral neoplasm in which there is a mixture 
of cystic, papillary and solid growth patterns. The solid areas are tan or 
white and contain foci of haemorrhage & necrosis 
17 
 Microscopy:  
 These tumors diffusely infiltrate a fibrotic stroma. Papillary growth is 
usually present atleast focally. Tumor cells are arranged in solid nests and 
sheets. The papillae lined by stratified low columnar cells, show marked 
nuclear atypia and frequent mitotic figures in high grade tumors. The stroma 
may be scanty or desmoplastic  with foci of necrosis.   
 
 
 
B)MUCINOUS TUMORS:  
 Mucinous tumors account for 12-15% of all ovarian tumors of which 
75% to 85% are benign, 10-15% borderline and remaining are frankly 
malignant. They attain largest size among ovarian neoplasms. 
Benign mucinous tumors:  
 Gross:Mucinous cynadenomas are cystic & generally unilateral. The 
average diameter is about 10cm. Cut surface reveals unilocular or 
multilocular mucin filled cysts of varying sizes
 17
 
Microscopy:  
    Characterized by a lining of tall columnar epithelial cells with apical 
mucin and the absence of cilia akin to benign cervical or intestinal epithelia. 
Borderline mucinous tumors:  
Gross:  
 These are large, with an average diameter of about 15cm. Most are 
multilocular, filled with mucin. 
Microscopy:  
    Two types:  
1.INTESTINAL TYPE : Most common type. 
        Crowding of complex glands, papillae supported by thin cores of 
fibrovascular connective tissue. Goblet cells are conspicuous, focal 
stratification of the cells into two or three layers. The tumor cells have round 
to oval vesicular nuclei with mild to moderate atypia, nucleoli may be 
prominent & occasional mitotic figures seen.
17
 
 
2.ENDOCERVICAL LIKE : 
             These tumors omprise 5-15% of borderline mucinous tumors. 
Branching papillary growth pattern  lined by columnar mucinous 
endocervical like cells and a variable number of cells with eosinophilic 
cytoplasm. Goblet cells  are absent, mitotic figures infrequent, minimal 
nuclear atypia present
83
 
 
Malignant mucinous tumors:  
 Mucinous carcinoma are less frequent than their serous 
counterparts.They differ from borderline tumors having evidence of ovarian 
stromal invasion. 
 
Gross:  
      Large, multilocular cystic tumor averaging 15-20cm in diameter.Firm, 
fleshy, white or tan solid areas,often with foci of haemorrhage or necrosis . 
<10% bilateral
11
 
 
Microscopy:  
 The glands and cysts are crossed and complex with irregular 
infoldings and protrusions into the surrounding stroma. Intestinal type cells 
predominate. The cells are columnar, have eosinophilic cytoplasm, and 
stratify into two or more layers. The nuclei are enlarged and vesicular with 
prominent nucleoli.Many typical and atypical mitotic figures, goblet cells 
and argyrophilic cells may be present.  
Pseudomyxoma peritonei : 
 Occurs in tumors of intestinal type. It is seen in borderline or 
malignant mucinous tumors, but can occur with large benign tumors also. 
The cells produce mucin which fills the abdominal cavity.  
 
C)ENDOMETRIOID TUMORS –  
  These tumors comprise 2-4% of all ovarian tumors. These tumors 
have an epithelial component that resembles proliferative hyperplastic or 
malignant endometrium.Occur most commonly in fifth and sixth decades
47
 
Benign & borderline tumors are rare.Endometroid Carcinomaaccount for 
about 20% of all ovarian cancers.15-20% coexist with endometriosis.15-
30%  are accompanied by carcinoma of endometrium. 
Gross:  
Cystic and  solid or completely solid tumor measuring 10-20cm 
diameter. Firm or soft , gray or tan with  haemorrhage and necrosis . Only 
10-20% are bilateral.  
Microscopy:  
 The growth pattern is glandular, papillary or mixture of two. The 
glands are small and relatively uniform in size and shape. The degree of 
atypia, nuclear stratification and the extent to which the glands coalesce into 
foci of solid growth increase as grade increases.
11 
 
 
 
 
D) Clear Cell Tumors:  
   These tumors comprise 5% of all ovarian cancers, common in age 
group 40 - 70 years.  Accompanied by both ovarian and pelvic 
endometriosis. More aggressive and more malignant than serous 
adenocarcinoma of ovary 
70
 
Gross :  
 These are unilateral and solid. They typically measure 10-15 cm in 
diameter. The cut surface is white gray or tan and contain small to medium 
sized cysts
11
 
 
Microscopy:  
 Tubules and cysts are lined by cuboidal or hobnail cells with clear or 
eosniophilic cytoplasm. These cells are irregularly distributed in a fibrous 
stroma.  
 The epithelium is stratified or tufted or grows as small circumscribed 
nests. The presence of mild to moderate nuclear atypia and scattered mitotic 
figures (usually <1 per HPF) differentiates  borderline clear cell tumors from 
a benign one. The absence of stromal invasion differentiates them  from 
clear cell carcinoma. 
 
 
 
 
E) TRANSITIONAL CELL TUMORS:  
 Ovarian tumors composed of epithelial elements histologically 
resembling urothelium and its neoplasms
58
. Comprise 1– 2% of all ovarian 
neoplasms. It comprises Brenner  and Non Brenner type. 
1)Brenner Tumor 
 In 1907C Fritz  Brenner was first to describe the cases of Brenner 
tumor which now bears his name. 
Approximately 95% of Brenner tumors are diagnosed in women between 
ages of 30& 70 yrs. It usually coexists with mucinous cystadenoma.
82
. Most 
Brenner tumors are benign,but borderline  and malignant Brenner have been 
reported. 
Gross:  
 Benign tumors are circumscribed, firm, pale yellow or gray white, 
solid fibrous  or cystic tumors. Usually unilateral, average size 1-2 cm
86 
 
Microscopy:  
The fibrous stroma is marked by sharply demarcated nests of epithelial cells 
resembling the transitional epithelial cells of  urinary tract often with 
mucinous glands in the centre. The nuclei are round or oval and have small 
nucleoli.A longitudinal nuclear groove is characteristic. 
 
 
 
 
2) Transitional cell carcinoma (Non-Brenner type)  
   
Gross :  
 Transitional cell carcinoma is a partly cystic tumor that averages 10 to 
15cm in diameter 
11 
Microscopy: 
 
 It is similar in appearance to malignant Brenner tumor except that 
Benign proliferating Brenner tumor is not identified and transitional cell 
carcinoma pattern must predominate ( 75%)
11 
 
II)SEX – CORD – STROMAL TUMORS 
              Neoplasms derived from the sex cords or ovarian mesenchyme 
comprise 5-12% of all ovarian neoplasms.  
 
A)GRANULOSA CELL TUMORS: 
 
 The tumor shows differentiation towards follicular granulosa cells
101
 
and comprise 1-2% of all ovarian tumors.These tumors secrete oestrogen 
which stimulates the endometrium to proliferate. The presentation may be 
post menopausal bleeding, menorrhagia, metrorrhagia  precocious 
puberty
27
. It  is associated with endometrial hyperplasia & endometrial 
carcinoma, cystic disease of breast.It has small(5-25%) but distinct hazard 
of malignancy(recurrence,extension) 
 
Two types: 
 Adult type occurs mainly in menopausal women and Juvenile type 
that occurs mainly in children
101
 
 
 a)Adult Granulosa Cell tumor:  
           In 1914,Von Werdt proposed the term “ Granulosa cell tumor”. 
 
Gross:  
 These range from few millimeter to 30 cm in diameter. Entirely solid 
but most are partly cystic. The solid portions are pink, tan, brown,  light 
yellow and vary from soft to firm in consistency
2
. 
Microscopy  
 The tumor cell resemble normal granulosa cells. Longitudinal folds or 
grooves are present in many nuclei giving a characteristic coffee bean 
appearance.   
 Several histologic patterns like follicular, trabecular, insular, watered 
silk pattern have been described. Of these the microfollicular pattern is the 
most characteristic and are termed Call-exner bodies.
1
 
  
b)Juvenile Granulosa Cell tumor: 
 
The incidence of Juvenile Granulosa Cell tumor in children is <5%. 
Average age is 15 years. But it can occur at any age from infancy to old age 
but most arise in children
17
 
 The tumor consists of both cystic & solid areas. Macrofollicular, solid 
and cystic growth patterns are characteristic.Focal or extensive luteinization 
is a typical finding. The tumor cell nuclei lack grooves and contain 
conspicuous nucleoli. 
B)FIBROMA – THECOMA GROUP
101 
 
 1)Thecoma 
  They account for 7% of sex cord stromal neoplasms. The average age is 
between 50 and 55 years
27
 .5% bilateral . 
Thecoma is a benign, firm tumor that varies in size from  l - 20cm in 
diameter. The cut surface is gray or tan, with extensive yellow areas
. 17.
The 
tumor is composed of fascicles or sheets of  spindle or ovoid cells. 
2) Fibroma 
It is the most common sex-cord stromal tumor accounting for 1-5% of 
ovarian tumor.Average age is 50 years or more. Meig’s syndrome, in which 
ovarian fibroma is accompanied by ascites and  hydrothorax. 
   Firm tumor with a smooth, lobulated surface. Size 1 - 10cm ,solid white or 
tan cut surface. Fibromas are composed of thin spindle cells growing in 
whorled and anastamosing bundles
101
. Mitotic figures are rare.  
 
c)SERTOLI  LEYDIG CELL TUMOR(ANDROBLASTOMA) 
 These tumors are seen in women of reproductive age, occurring 
unilaterally causing masculinization.Cut surface  gray to  golden yellow. 
 Microscopically well differentiated tumors show tubules composed of 
sertoli or leydig cells interspersed with stroma. The intermediate forms 
show only outlines of immature tubules & large eosinophilic leydig cells. 
Poorly differentiated tumors have a sarcomatous pattern with a disorderly 
disposition of epithelial cell cords.Leydig cells may be absent. 
 
III)GERM CELL TUMORS  
  Germ cell tumors represent 15-20% of all ovarian tumors 
33
.   They 
are composed of cells derived from oocyte
46
. Most of these tumors are seen 
in children and young adults. Younger the patient, the more likely the germ 
cell tumor to be malignant.
57 
 
 
 
 
A)Dysgerminoma: 
 
              Mayer first applied the name Dysgerminoma in 1931 to a solid 
carcinomatous ovarian tumor histologically resembling testicular seminoma. 
It is the most common(50%) of all malignant germ cell tumors of the 
ovary
15
.  
Dysgerminoma is a large solid tumor usually more than 10cm in diameter,  
with convoluted outer surface. Usually unilateral, cut surface shows 
haemorrhage and necrosis in 50% of cases. 
85
.  
 The tumor is composed of large round to polygonal uniform cells with 
vesicular nuclei and prominent nucleoli, abundant clear to finely granular 
cytoplasm that contains glycogen and separated by thin fibrous septa which 
shows lymphocytic infiltration
85
.  
 
B)Yolk sac tumor( Endodermal sinus tumor):  
          
           Yolk sac tumor is rare but it is the second most common malignant 
tumor of germ cell origin 
85
. Occurs in  2
nd
 and 3
rd
 decade.Prognosis is very 
poor.  
 
 
 
Gross:  
 These are large, encapsulated, solid  tumor with smooth and glistening 
external surface. The tumor has variegated cut surface.  
Microscopy:  
 Yolk sac tumor shows variable microscopic appearance  
31
. The 
festoon pattern containing pseudopapillary processes with central vessel (ie) 
Schiller Duval bodies described by Schiller.  Other patterns  are  microcystic 
(reticular) , solid , polyvesicular vitelline pattern.   
  
C) Embryonal carcinoma :  
         
                 Embryonal carcinoma is seen more commonly in mixed germ cell 
tumors of ovary. Pure form is extremely rare.  5% of malignant germ cell 
tumors are of this category. Occurs in 2
nd
 and 3
rd
 decade of life.  
Gross:  
 These tumors are large with smooth & glistening external surface and 
having variegated cut surface with extensive areas of haemorrhage and 
necrosis.  
Microscopy:  
 These tumors are composed of solid sheets and nests of large 
primitive cells,  syncytiotrophoblast like tumor cell and tumor giant cells are 
seen frequently. These are HCG positive immunohistochemically
85
. 
Prognosis is very poor. 
 D) Choriocarcinoma:  
 These tumors are  more commonly of placental origin. Primary 
ovarian choriocarcinoma is exceedingly rare. It is divided into gestational 
type from placental origin and nongestational type from germ cell origin 
30
.Ovarian gestational choriocarcinoma can be primary or metastatic from 
uterine or tubal pregnancy. As the tumor is associated with high HCG 
levels, its diagnosis especially in young women is most often confused with 
an ectopic pregnancy 
60,95
 
Gross:  
 The tumor has smooth or nodular external surface. The cut surface 
shows variegated appearance, gray white with areas of haemorrhage and 
necrosis.  
 
Microscopy:  
 The tumor shows admixture of cytotrophoblast and 
syncytiotrophoblast, the latter form villous like structures around the 
cytotrophoblast in a necrotic or haemorrhagic background 
85
. 
 Prognosis is poor. Gestational Choriocarcinoma has better prognosis 
& respond to chemotherapy in contrast  to  non – gestational counterpart.  
 
E) Teratoma:  
 Willis (1960) had given a vivid description the genesis of teratomas. 
According to him teratomas  are the tumors arising from foci of pluripotent, 
embryonic tissue  that  escapes from the influence of the primary organizer 
during embryonic development. 
         Teratomas form the commonest group of germ cell tumors in the 
ovarian neoplasm. They constitute  25.86% of all ovarian tumors. 
Depending upon the nature of the tissue component 
41
,they are classified  
into mature and immature teratoma. 
1.Mature cystic teratoma(Benign) : 
             These are the most common variety of germ cell tumors accounting 
for more than 95% of ovarian teratomas and 15-20% of neoplasm in general 
94 
 
These are usually found in young women during the active reproductive 
years 
103
. 
 
Gross:  
 They are unilateral in 88% of cases. Characteristically they are 
unilocular cysts containing greasy material composed of keratin, sebum and 
tuft of hair 
85
. Within the wall, tooth structures and areas of calcification  
may be seen.  
Microscopy:  
 Black well et al (1946) 
9
 found ectodermal derivatives in 100% of 
tumors, mesodermal derivatives in 93% and endodermal structure in 71% of 
cases. The tumor shows cyst lined by squamous epithelium in nearly all the 
cases with skin appendages and other elements like fat, cartilage, smooth 
muscle and bone. Endodermal structures like bronchial & gastrointestinal 
epithelium are seen. Neural & thyroid  tissue are also seen. 
2.Immature  teratoma: 
                  These are rare tumors that differ from benign teratomas with 
component  resembling embryonal and immature  fetal tissue.Mean age of 
presentation is 18 yrs.Unilateral, large bulky with smooth external surface. 
Cut surface mostly solid with haemorrhage & necrosis. Microscopically  
varying amounts of immature epithelium, hair, cartilage,  bone , calcification   
may be seen.Histological grading  is done by assessing the amount of 
immature tissue and neuroepithelium. 
3.Monodermal or specialized teratomas: 
 These specialized teratomas comprise a rare group ,of which struma 
ovarii and carcinoid are the most common. They are always unilateral. 
Struma ovarii is composed entirely of mature thyroid tissue. The ovarian 
carcinoid presumably arises from the intestinal epithelium in a teratoma.         
 Secondary malignancies in benign cystic teratoma are rare.Cutaneous 
adnexal neoplasms,benign salivary gland type tumors, meningioma, glomus  
tumor.Invasive squamous cell carcinoma is common and  comprises 
85%.Other tumors are basal cell carcinoma,melanoma,adenocarcinoma, 
sarcoma etc.  
 
 
 
METASTATIC TUMORS 
 
The most common  metastatic tumors of the ovary are derived from tumors 
of mullerian origin:uterus, fallopian tube, contralateral ovary or pelvic 
peritoneum. The most common extra mullerian tumors metastatic to ovary 
are  carcinoma of  breast  and  gastrointestinal tract including colon, 
stomach, biliary tract and pancreas. Comprises 10% of all ovarian cancers
81
. 
  The characteristic features of metastatic disease are bilateral presentation 
with smaller size than primary ovarian tumors, nodular growth pattern, 
surface involvement, infiltrative growth. 
KRUKENBERG TUMOR:  
A classical example of  metastatic  gastrointestinal neoplasia to the ovaries,   
characterized by bilateral metastases composed of mucin  producing   signet 
ring  cells, most often of gastric origin. 
  
                          
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Materials and Methods   
 
 
                        MATERIAL AND METHODS 
 
This prospective study is undertaken in the Department of Pathology, 
Madurai medical college, Madurai during the period 2009-2011.This study 
was conducted on 200 ovarian neoplasms (Ann.VI) out of 239 ovarian 
lesions received after exclusion of non-neoplastic lesions. This study was 
approved by the institutional ethical committee (Ann IV). 
            The tissue samples included in this study were 91 ovariotomy 
specimens and  109 hysterectomy with ovariotomy specimens received   in 
buffered 10% neutral formalin  from Government Rajaji Hospital, Madurai. 
A detailed history regarding  clinical symptoms and signs were recorded and 
thorough gross examination in particular attention to laterality, size, 
consistency of the specimens were also done.(Ann I). 
            After adequate fixation, representative bits were taken. In cystic 
ovarian neoplasms, 4-5 bits were taken. In solid tumors, if <5cm, 3-4 bits 
were taken. If more than 5cm, 1 block per 1 cm of the tumors were taken 
across  its greatest dimension, particularly if the appearance is variegated.   
           Tissue bits fixed in 10% buffered neutral formalin were processed in  
automated tissue processor. Sections were made manually with microtome 
of thickness 3-5 micrometer and  routinely stained with hematoxylin and 
eosin stains.         Special stains like Periodic Acid Schiff (PAS), Reticulin 
were done using standard  procedures to study their different pattern of 
expression in different tumors.  Reticulin stain was done for all the 
Granulosa cell tumors (10 cases) and all  Fibrothecomas (3 cases). PAS stain 
was done in all mucinous cystadenocarcinomas (8 cases) and  all 
Krukenberg tumors (3cases). 
(Ann II). These tumors were then tumors were classified according to WHO 
classification of ovarian tumors (Ann III). 
             Ki 67 protein is a cellular marker for nuclear proliferation which is 
present in all phases  of cell cycle (G1S,G2M) and is absent in resting phase 
(G0).It is an excellent marker to determine the growth fraction of a given 
cell population. The fraction of Ki 67 positive tumor cells (Ki 67  labelling 
index ) is often correlated with the clinical course of cancer.            
          Ki 67 immunohistochemical proliferative marker study using 
peroxidase-antiperoxidase technique (Ann II) was done in 24 selected cases 
which comprised benign ,borderline and malignant ovarian tumor. 
          Positive Ki 67 staining was observed as brown granular nuclear 
staining. For Ki 67 scoring the most positive area of the tumor was selected 
avoiding foci of inflammation. The number of positive nuclei is counted in 
500 tumor cells in  a high power field(x 400 magnification). The average of 
3 counts over the same slide was taken and expressed as the percentage of 
Ki 67 positive cells in the tumor. 
  The expression of immunohistochemical markers like vimentin, inhibin, 
EMA , cytokeratin and chromogranin  was studied in  10 ovarian tumors 
which were histopathologically diagnosed as Granulosa cell tumors.  
 
 
 
 
 
 
 
 
 
 
 
 
 
                  
                 
 
 
 
 
 
 
 
 
 
 
 
Observation & results    
OBSERVATION AND RESULTS 
  
             In the present study, a total of 7964  gynaecological  specimens were 
received in the Department of Pathology, Madurai medical college, Madurai. 
Among them 882 cases were gynaecological malignancies including 239   
ovarian  lesions and in that  after exclusion of non –neoplastic  lesions , 200  
were ovarian  neoplasms   constituting 2.5 %. 
   
  
THE DISTRIBUTION OF INDIVIDUAL OVARIAN TUMORS:  
                        Among 200 cases of ovarian tumors studied  155 cases were 
surface epithelial tumors (77.5 %),22 cases were germ cell tumors(11%),15 
cases were sex cord stromal tumors(7.5%),  5 cases were unclassified 
(2.5%), 3 were  krukenberg  tumors(1.5%) . 
             Out of 200 cases,124 were benign(62%) ,11 were borderline(5.5%) , 
65 were malignant tumors(32.5%).Three  patients had both benign and 
malignant tumors. They were included under malignant tumors.  
           
               
 
 
The  distribution of cases has been illustrated in table 1. 
Table  1 : Diagnosis  and type of tumor 
 
Type of tumor 
Benign Borderline Malignant 
 
Diagnosis 
No. 
of 
cases No % No % No % 
I.Surface  epithelial 155 98 63.2 11 7.1 46 29.7 
II. Sex cord stromal 15 15 100 - - -        - 
III. Germ cell tumor 22 13 59.1 - - 9 40.9 
IV. Metastasis 3 - - - - 3 100 
V. Unclassified 5 - - - - 5 100 
Total 200 124  11  65  
 
 
 
 
 
graph 1 : Diagnosis  based on cell of origin 
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AGE  INCIDENCE OF   OVARIAN TUMORS: 
 
 According to this study , ovarian neoplasms occur in the age group 
between 2 to 76 years. There was a high incidence of ovarian neoplasms in 
the age group of 41-50 years. The youngest patient in this study was 2 years 
old who presented with precocious puberty  and  was diagnosed as Juvenile 
granulosa cell tumor.The oldest patient was 76 years old ,presented with 
mass abdomen (15x13x6) and  was diagnosed as Fibrothecoma. 
               Benign tumors were more common in age group 21-30 years, 
Borderline in more than 60 years, malignant in age group 41-50 
years.Benign tumor cases had lower mean age and borderline tumor cases 
had higher mean age. But the difference was not statistically significant. 
 
Table -  2 : Age and type of tumor 
Type of tumor 
Benign Borderline Malignant 
Age group No. 
of 
cases No % No % No % 
Upto 20 years 15 10 66 - - 5 33.3 
21- 30 years 39 31 79.5 1 2.6 7 17.9 
31- 40 years  46 27 58.7 3 6.5 16 34.8 
41- 50 years 56 31 55.4 3 5.4 22 39.3 
51- 60 years  29 18 62.1 1 3.4 10 34.5 
> 60 years  15 7 46.7 3 20 5 33.3 
Total 200 124 62 11 5.5 65 32.5 
  
Mean 
SD 
  
39.3 years  
14.3 years 
 
48.4 years 
14.8 years 
 
42.6 years 
13.2 years 
 
 
   
 
 
 
 
 
 
 
 
graph 2 :  Age and type of tumor 
CLINICAL FEATURES 
 All the cases were evaluated clinically at the time of admission as in 
the following table. Abdominal mass was the most common clinical 
presentation (117 cases, 58.5%) followed by pain (101 cases, 50.5%).  Other 
symptoms like  menstrual disturbances, precocious puberty, weight loss, 
abdominal distention urinary frequency, constipation were present in 6 
cases(3%). Many cases had more than one clinical features 
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Table – 3: Clinical Features  
Cases  
Clinical features 
No % 
Mass 117 58.5 
Abdominal Pain 101  50.5 
Menstrual disturbance 10 5 
Other symptoms 6 3 
  
                        
Graph 3 Clinical Features 
 
 
 
 
  SIZE OF THE OVARIAN TUMORS: 
                The largest ovarian tumor in this study was  Benign mucinous 
cystadenoma measuring 30x25x10 cm and smallest tumor was a Benign 
serous cystadenoma measuring 2x2x0.5 cm. The size of the ovarian tumor in 
this study ranged from 2.5cm to 30cm. The average size was 9 cm. 
                                       
Graph 4   
Size 
 
 . 
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 CONSISTENCY OF OVARIAN TUMORS: 
 
          The consistency of ovarian tumors was cystic in 115 tumors( 57.5%), 
solid in  69 tumors(34.5%) and partly cystic and solid in 16 tumors( 8%). 
           Consistency was cystic in majority (85.5%) of benign tumor cases.. It 
was solid in 81.5% of malignant cases. Papillary lesions were seen in 31 
ovarian tumors. 
 
Graph 5 
Type of tumor and consistency 
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 LATERALITY OF OVARIAN TUMORS 
                  In the present study ,out of 200 cases 163(81.5%) were unilateral 
and 37 were bilateral (18.5%)In that 90.3% of benign ovarian tumors were 
unilateral and 64.6% of malignant ovarian tumors were unilateral, whereas 
9.7% of benign ovarian tumors were bilateral and 35.4% of malignant 
ovarian tumors were bilateral. . 
 Bilaterality is more common in serous than mucinous tumors. Unilaterality 
is more common in sex cord stromal tumors (93.3%), bilaterality more 
common in metastatic tumors(66.7%). The more common surface epithelial 
tumors show unilaterality in 81.3 % of cases and  bilaterality in 18.7% cases. 
 
Table 4   
Diagnosis and Laterality 
Laterality 
Unilateral Bilateral 
 
Diagnosis 
No. of 
cases 
No % No % 
I.Surface epithelial 
tumors 
155 126 81.3 29 18.7 
II. Sex cord stromal 15 14 93.3 1 6.7 
III. Germ cell tumor 22 19 86.4 3 13.6 
IV. Metastasis 3 1 33.3 2 66.7 
V. Unclassified 5 3 60 2 40 
Total 200 163 81.5 37 18.5 
As severity of tumor increases, laterality becomes more bilateral. 
 
 
27, 13%
173, 87%
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 METASTASIS OF OVARIAN TUMORS 
 
 
 Metastasis to omentum, ascites were present in 41.5% of malignant tumors. 
 
 
Graph 6   
 
Metastasis 
 
  HISTOLOGICAL TYPES OF OVARIAN TUMORS 
 SURFACE EPITHELIAL STROMAL TUMORS 
 This was the commonest group encountered in the present study ,155 
cases  out of 200  were Surface Epithelial tumors.(77.5%). 31 cases  showed  
papillary pattern.(fig 15) .The distribution of  Surface  Epithelial tumors 
encountered in this study has been illustrated in the table 5.       
Table 5 
Cases Diagnosis 
No % 
I. Surface epithelial tumours  
a) Cyst 
i) Benign serous cyst 
ii) Benign mucinous cyst 
     Total 
 
 
8 
1 
10 
 
 
4 
0.5 
5 
b) Cyst adenoma 
i) Benign serous cystadenoma 
ii) Benign mucous cystadenoma 
 Total 
 
50 
38 
88 
 
25 
19 
44 
c) Borderline 
i) Borderline serous cystadenoma 
ii) Borderline mucous cystadenoma 
 Total 
 
1 
9 
10 
 
0.5 
4.5 
5. 
d) Malignant 
i)Serous adeno carcinoma 
ii) Mucinous adrnocarcinoma 
 Total 
 
35 
8 
43 
 
17.5 
4 
21.5 
e) undifferentiated tumors 5 2.5 
 
   TOTAL 155  
 
 
 
 
 
SEX-CORD STROMAL TUMORS 
                 15 sex cord stromal tumors   which were encountered in the 
present study have been  depicted in table 6. 
 
Table 6 
 
TUMOR TYPE No.  OF CASES % 
a) Granulosa cell tumor 
b) Fibrothecoma 
c) Fibroma  
    Total 
10 
3 
2 
15 
5 
1.5 
1 
7.5 
 
               Among 15 cases, 10 were histopathologically diagnosed as  Adult 
Granulosa cell tumor.   These tumors showed   microfollicular, insular and 
watered silk pattern with Call-Exner bodies (Fig21). A case of juvenile 
granulose cell tumor was reported (fig22).Two  cases of fibroma and three 
cases of fibrothecoma were recorded in this series (1%) .  
        
            In this study, we applied reticulin stain for all the  Granulosa cell 
tumors(10 cases) and  all the cases of fibrothecomas(3 cases). The stain 
shows fibrils surrounding the nests and large aggregates of granulosa cells in 
Granulosa cell tumors (fig 24). In Fibrothecoma, reticulin stain highlights an 
investment of individual cells by fibrils. 
 
 
GERM CELL TUMORS 
                 
                22 germ cell tumors   which were encountered in the present study 
have been depicted in table 7. 
                                                   
Table 7 
 
TUMOR TYPE No.  OF CASES % 
 
a) Teratoma 
b) Dysgerminoma 
c) Yolk sac tumor 
d) Embryonal carcinoma 
            Total 
 
15 
3 
4 
- 
22 
 
7.5 
1.5 
2 
- 
11 
 
  
             In the present study  out  of  22 germ cell tumors, 15 cases were 
diagnosed as benign cystic teratoma (7.5%).Tumors showed presence of 
squamous epithelium and dermal appendages, fat, cartilage, respiratory and 
gastrointestinal epithelium    (fig.29).One case of immature teratoma with  
neuroectodermal elements was encountered (fig.30). 
             Three cases of dysgerminoma were encountered. The tumor was 
grey white nodular external surface (cerebriform) with intact capsule( 
fig11).Four cases of yolk sac tumor encountered. Tumor  arranged in 
reticular patter and endodermal sinus pattern with Schiller–Duval bodies (fig 
28). Intracellular and extracellular hyaline globules were seen. 
METASTATIC TUMORS / KRUKENBERG TUMORS 
 
 In the present study, 3 cases of krukenberg tumors were noted. Tumor 
was solid in consistency( fig 13). Histologically composed of signet ring 
cells  admixed with  benign appearing mucinous areas( fig 32).  
           Primary carcinoma were in stomach in 2 cases. In our study mucinous 
carcinoma of ovary shows extra cellular PAS positive mucin pools (fig 34) 
where as in Krukenberg tumor show intracellular PAS positivity in signet 
ring cells  (fig 33). 
 
 PROLIFERATIVE MARKER STUDY 
  
RESULTS OF Ki 67 LABELLING INDEX 
 
 Ki 67 labelling index was studied in 24 selected cases which 
comprised  of 4 benign cystadenoma  (2 serous,2 mucinous), 4 borderline 
cystadenomas(2 serous,2  mucinous), 4 carcinoma (2 serous, 2 mucinous 
adenocarcinoma), 2 germ cell tumors , all the 10 Granulosa cell tumors.        
One way analysis of variance test was used to assess the statistical difference 
between  Benign,borderline & malignant epithelial ovarian tumors. 
   The comparative analysis of Ki 67 labelling index has been shown in table 
8. 
               
                 COMPARATIVE ANALYSIS OF Ki 67 LABELLING INDEX 
Table 8 
 
 
The results were 
  a) Both cases of  benign serous cystadenomas had a mean Ki 67 index of 
2.8 % and both cases of  benign mucinous cystadenomas had a mean Ki 67 
index of 3 %   (fig 36 ) 
  b) Two cases of  borderline serous cystadenomas  had a mean Ki 67 index  
of   8.3 % and both cases of borderline mucinous cystadenomas  had a mean 
Ki 67 index of  6.1% (fig 38). 
  c) Both cases of malignant serous cystadenocarcinomas had a mean Ki 67 
index of 29.1 % and both cases of mucinous cystadenocarcinomas    had a 
mean  Ki 67 index of 32.4 %  (fig 40). 
s.no                  
            TYPE OF CASES 
NO.OF 
CASES 
 Ki67 
INDEX 
1 BENIGN  SEROUS CYSTADENOMA 2 2.8 
2 BENIGN MUCINOUS CYSTADENOMA 2 3.0 
3  BORDERLINE SEROUS CYSTADENOMA 2 8.3 
4 BORDERLINE MUCINOUS 
CYSTADENOMA 
2 6.1 
5 SEROUS CYSTADENOCARCINOMA 2 29.1 
6 MUCINOUS CYSTADENOCARCINOMA 2 32.4 
7 DYSGERMINOMA 1 25.3 
8 YOLK SAC TUMOR 1 31.3 
 d) Both the cases of germ cell tumors showed an average Ki 67 index of 
28.3% (fig42). 
Benign tumors had a mean Ki 67index of  2.9% , borderline tumors had a 
mean  Ki 67 index of  7.2%  ,while the malignant tumors had a mean Ki 67 
index of 29.9% . 
          The difference in the mean value between benign, borderline, and 
malignant epithelial tumors were statistically significant (p =<0.001). 
 
IMMUNOHISTOCHEMICAL MARKER STUDY IN GRANULOSA 
CELLTUMORS (GCT): 
 
             We received a  total of 10 cases of Granulosa cell tumors in our 
study.  
Out of  the ten cases which were histopathologically diagnosed as Granulosa 
cell tumor, two cases turned out to be  primary ovarian carcinoid and poorly 
differentiated carcinoma  respectively after immunohistochemical study.  
  The results of expression of various immunomarker in all these tumors are 
shown in table 9. 
 
 
 
 
Table 9 
S.N case vimentin Inhibin  chromogranin EMA Ki 67 index STAGE 
1 G2955/09 + + -    - 5.4 I(a) 
2 G4613/09 + + -    - 4.8 I(a) 
3 G1879/10 + + -    - 4.4 I(a) 
4 G1888/10 + + -    - 7.9 I(c) 
5 G2652/10 + + -    - 2.8 I(a) 
6 G3169/10 + + -    - 3.4 I(a) 
7 G3928/10 + + -    - 4.2 I(a) 
8 G762/11 + + -    - 8.4 I(c) 
9 G232/10 - - +    - 3.0  
10 G1857/10 - - -    + 25.1  
 
  
DIAGNOSTIC SIGNIFICANCE OF IMMUNOHISTOCHEMICAL 
STUDY  IN GRANULOSA CELL TUMORS: 
 
1. GCT TURNED OUT TO BE PRIMARY OVARIAN CARCINOID 
AFTER IHC: 
      We received a clinically suspected specimen of ovarian tumor  in a 55 
year old postmenopausal woman.Grossly , it was a large yellowish tumor of 
size 12x11x11 cm with predominant solid areas. Initially histopathological 
diagnosis of Granulosa cell tumor/Carcinoid tumor were considered. With 
immunohistochemical study, tumor cells showed strong expression of 
chromogranin and synaptophysin and   was negative for vimentin.. Final 
diagnosis of Ovarian Carcinoid was made. 
 (fig 25,26) 
       On retrospective analysis, no other tumor mass was detected elsewhere 
by abdominal ultrasonography and CT scan. Isolated Tricuspid regurgitation 
was incidentally found in pre-operative echocardiography. 
         In correlation with the above findings, we came to conclusion of 
Primary Ovarian Carcinoid tumor with Tricuspid regurgitation. 
 
 
2.GCT TURNED OUT TO BE  A POORLY DIFFERENTIATED 
CARCINOMA AFTER  IHC : 
 
          In another case of ovarian tumor received, provisional diagnosis of 
Granulosa cell tumor was made based on histopathological features. On 
further evaluation with immunohistochemical markers Vimentin and Inhibin 
were negative and EMA  was positive and so the final diagnosis of poorly 
differentiated carcinoma was made . 
 The remaining  8 cases  showed vimentin  positivity and EMA 
negative.These tumors were diagnosed as  Granulosa cell tumors . 
 
Ki 67 LABELLING  INDEX IN GCT: 
 
        Mean Ki 67 index for 8 cases of histologically and 
immunohistochemically proven case of granulosa cell tumor was 5.1%. 
   In the present study ,  Ki 67 index was higher in  2 cases of. Granulosa cell 
tumors (7.9% and 8.4%) which correlated clinically with higher stage (FIGO 
stage I(c) disease). 
    Ki 67 index in the rest of the Granulosa cell tumors was low which 
correlated clinically with  FIGO stage I(a) disease.  
       Thus in the present study, Ki 67 index reflected more closely the clinical 
behavior and clinical stage of Granulosa cell tumors tumors (fig 44). 
 
 
 RETICULIN STAIN IN GRANULOSA CELL TUMOR: 
 
In this study, we applied reticulin stain for all granulosa cell tumors 
and fibrothecomas (3 cases). The stain shows fibrils surrounding  nests and 
large aggregates of granulosa cells( fig 24). In Fibrothecoma,  reticulin stain 
highlights an investment of individual cells by fibril. 
 
 
INTERESTING  TUMORS: 
               
        In this study we came across 7 interesting cases .They  are as follows 
 
1. MIXED TUMORS: 
                  2 cases of mixed epithelial tumors  were observed. Combinations 
of mucinous cystadenoma of ovary with benign Brenner tumor in the same 
ovary in both cases.(fig18) 
2.BILATERAL MALIGNANT BRENNER: 
 
      One case of bilateral malignant Brenner tumor was observed in a 65 year 
old female who presented with abdominal mass. Grossly the tumor measured 
10x8x5 cm and 4x3x2 cm on each side. The tumor was arranged in sheets 
with stromal invasion.(fig 20) 
3. JUVENILE GRANULOSA CELL TUMOR :  
 
          One case of Juvenile granulosa cell tumor in a 2 year old girl who 
presented with precocious puberty( breast enlargement, vaginal bleeding). 
Grossly the tumor measured 8x6x5 cm. Both  solid  and  cystic areas  were 
seen(fig 10) 
Microscopically the tumor showed predominantly macrofollicular 
pattern.(fig 22 ) 
4. IMMATURE TERATOMA: 
         One case of immature teratoma with neuroectodermal elements was 
encountered (fig.30). 
 
 
5.GCT  WITH ASSOCATED ENDOMETRIAL CARCINOMA: 
 
         One case of unilateral granulosa cell tumor in a 65 year old female was 
associated with well differentiated endometrial adenocarcinoma with 
omental metastatic deposits. 
 
 
6.CYSTIC TERATOMA WITH MALIGNANT EPITHELIAL 
COMPONENT: 
         Secondary malignancies in benign cystic teratoma are rare. Invasive 
squamous cell carcinoma is common and  comprises 85%.But we  
encountered a relatively rare association of adenocarcinoma occuring  as a 
secondary  malignancy in benign cystic teratoma in a 45 year female.  
 
7.OVARIAN NEOPLASM  WITH ASSOCIATED ENDOMETRIAL 
CANCER: 
         Out of 200 ovarian tumors, 5 were associated with endometrial 
carcinoma (2.5%). Among those 5cases,3 showed the same histologic 
pattern in both ovary and endometrium. One case  was ovarian Granulosa 
cell tumor with endometrial adenocarcinoma and the other was  bilateral 
mucinous cystadenoma with endometrioid type of endometrial 
adenocarcinoma. 
                                            
 
 
 
 
 
        TABLE 10 
S.No BIOPSY 
NO 
OVARIAN 
TUMOR TYPE 
ENDOMETRIAL 
CARCINOMA 
TYPE 
OTHER 
FEATURES 
1 G2575/09 b/l endometrioid 
carcinoma  
endometrioid 
carcinoma 
 
2 G2125/09 b/l mucinous 
cystadenocarcinoma 
well differentiated 
mucin secreting 
adenocarcinoma 
 
3 G4613/09 papillary 
cystadenocarcinoma 
papillary 
adenocarcinoma 
fallopian tubes 
tumor + 
4 G762//11 u/l granulosa cell 
tumor  
well differentated 
adenocarcinoma 
omentum 
tumor + 
5 G695/11 b/l mucinous 
cystadenoma 
endometrioid type 
of adenocarcinoma 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Photographs     
 
 
 
           
 
BENIGN PAPILLARY SEROUS CYSTADENOMA 
Fig.3 G4026/09 Glistening cyst wall with papillary excrescences 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BENIGN MUCINOUS CYSTADENOMA 
Fig.4 G3577/10 Cystic mass filled with mucinous material 
 
 
PAPILLARY SEROUS CYSTADENOCARCINOMA 
Fig.5 G60/11 C/S solid and cystic with papillae 
 
 
 
B/L ENDOMETRIOID CARCINOMA 
Fig.6 G2575/09 C/S showing greyish-white solid areas 
 B/L MALIGNANT BRENNER TUMOR 
Fig.7 G 476/11 C/S solid and yellowish white areas  
 
 
 
FIBROMA 
Fig.8 G1137/11 Cut surface showing uniformly whitish solid areas 
ADULT GRANULOSA CELL TUMOR 
Fig.9 G1888/10 C/S  solid yellowish areas with cystic degeneration 
 
 
JUVENILE GRANULOSA CELL TUMOR 
Fig.10 G3928/10 Cut surface solid and cystic with areas of 
hemorrhage 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DYSGERMINOMA 
Fig.11 G1920/10 Typical lobulated outer surface 
 
 
BENIGN CYSTIC TERATOMA 
Fig.12 G 2081/10 Admixture of sebum and hair within  
the cystic cavity 
 
 
Fig.13 G 1891/10 B/L KRUKENBERG TUMOR 
WITH OMENTAL DEPOSITS 
 
OVARIAN CARCINOID TUMOR 
Fig.14 G232/10  
 
 
 
Fig. 15: G1673/10 PAPILLARY SEROUS CARCINOMA 
Tumor cells arranged in papillary pattern with fibrovascular core 
with insert showing psammoma bodies (H&E x 100x)  
 
 
 
MUCINOUS CYSTADENOCARCINOMA 
Fig.16 .G 934/11 Confluent pattern of growth with back-to-back glands 
with mucinlakes(H&E x 100X) 
 
 
ENDOMETRIOID CARCINOMA 
Fig.17 G2575/09 Back-to-back glands lined by columnar cells with 
stratified hyperchromaticnuclei(H&E x 100X) 
 
 
MIXED EPITHELIAL TUMOR-BRENNER TUMOR WITH 
MUCINOUS CYSTADENOMA 
Fig.18 G 884/10(H&E x 100X) 
 
 
 
Fig.19 BRENNER TUMOR SHOWING EPITHELIAL NESTS 
EMBEDDED WITHIN FIBROUS STROMA   G 4175/11( H&E x 100X) 
 
 
 
BILATERAL MALIGNANT BRENNER 
Nests and islands of tumor cells  
infiltrating the stroma.  Fig.20 G 476/11 (H&E x 100X) 
 
ADULT GRANULOSA CELL TUMOR 
Fig.21 G3713/11 Watered silk pattern with insert showing 
Call Exnerbodies(H&E x 100X) 
 
 
 
 
  
 
 
 
 
 
 
 
 
JUVENILE GRANULOSA CELL TUMOR 
Fig.22 G3928/10 Irregular macrofollicles filled with eosinophilic 
secretions and surrounded by neoplastic granulosacells(H&E x 
100X) 
 
ADULT GRANULOSA CELL  TUMOR 
Fig.23 G 3713/11Vimentinpositivity(H&E x 400X) 
 
 
ADULT GRANULOSA CELL TUMOR 
Fig.24 G 1888/10 Exhibitingreticulin wrapping  
around nests (H&E x 100X) 
 
CARCINOID TUMOR 
Fig.25 G232/10Insular pattern(H&E x 100X) 
 
CARCINOID TUMOR 
Fig.26 G232/10 Chromogranin positivity(H&E x 100X) 
 
 
 
 
FIBROTHECOMA 
Fig.27 G4444/09Pale lipid containing theca cells merge  
with spindle cell areas characteristic of fibroma(H&E x 100X) 
 
 
 
 
YOLK SAC TUMOR WITH INSERT SHOWING 
 SCHILLER- DUVAL BODIES 
Fig.28 G3173/10(H&E x 100X) 
 
BENIGN CYSTIC TERATOMA  
Fig. 29  G 2081/10  showing areas of cartilage, hair,  
squamous epithelial lining (H&E x 100x)  
 
 
 
OVARIAN IMMATURE TERATOMA 
With Primitive neuroepithelial elements 
Fig.30 G2016/10(H&E x 100X) 
  
 
UNDIFFERENTIATED CARCINOMA 
Fig.31 Sheets of pleomorphic epithelial cells with  
marked nuclear atypia G 1644/10 (H&E x 100X) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
KRUKENBERG TUMOR  
Fig.32 G1891/10 Insert showing signet ring cells. (H&E x 100X) 
 
KRUKENBERG TUMOR  
Fig.33 G1891/10 Signet ring cells showing PAS positivity  
 (H&E x 400X) 
 
 
MUCINOUS CYSTADENOCARCINOMA  
Fig. 34 G934/11 Tumor Cells with extracellular mucin pools showing PAS 
positivity (H&E x 400X)
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BENIGN MUCINOUS CYSTADENOMA 
Fig.35 G 3577/10 Cyst lined by columnar cells with bland basal nuclei and 
apical mucin(H&E x 100X) 
 
 
 
BENIGN MUCINOUS CYSTADENOMA   
Fig.36 G 3577/10 Ki-67 index 3.1%(H& E x 400X) 
  
 
BORDERLINE MUCINOUS CYSTADENOMA 
Fig.37 G4079/10(H&E x 100X) 
 
 
 
BORDERLINE MUCINOUS CYSTADENOMA 
Fig.38 G4079/10(H&E x 100X) Ki-67 index 6%(H& E x 400X) 
  
 
 
Ki67 MALIGNANT 
 
 
 
 
 
Figure - 
 
 
 
 
 
 
 
 
 
 
 
PAPILLARY SEROUS CYSTADENOCARCINOMA 
Fig.39 G 104/10 Tumor cells arranged in solid nests and papillary 
pattern  (H& E x 100X) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PAPILLARY SEROUS  CYSTADENOCARCINOMA 
Fig.40 G 104/10(H& E x 400X) Ki-67 index 29% 
 
DYSGERMINOMA 
Fig.41 G1920/10 Well defined nest of tumor cells separated by fibrous 
strands infiltrated by lymphocytes(H& E x 100X) 
 
 
DYSGERMINOMA  
Fig.42 G1920/10 Ki-67 index 25.3% 
 
 
ADULT GRANULOSA CELL TUMOR 
Fig.43 G2652/10 (H&E x 100X) 
 
 
  
ADULT GRANULOSA CELL TUMOR 
Fig.44 G2652/10  Ki-67 2.8%(H&E x 400X) 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion  
 
DISCUSSION 
 
 The tumors of the ovary pose a major problem to the gynaecologist 
due to their higher complication rate and they are the biggest diagnostic 
challenge in the field of gynaecological oncology. The absolute number of 
the new cancer patients in India is increasing rapidly due to an increase in 
the size of the population as well as an increase in the proportion of elderly 
persons due to improved life expectancy
59
. The increased incidence of cases 
is partly due to more widespread screening programmes, improved 
certification and registration procedures in certain countries.  
 
 Though many authors have worked extensively in the field of ovarian 
tumor pathology, the wide variation in facts and figures from these studies 
causes the confusion in the area of tumor nomenclature and different 
morphological subtypes of tumor. In this study, an attempt has been made to 
study the histomorphology of ovarian tumors,and usefulness of 
immunohistochemical markers for accurate diagnosis and to assess the 
prognosis using Ki 67 immunoproliferative marker. These  results are 
correlated with other studies.  
 
INCIDENCE OF OVARIAN TUMORS:  
The comparison of incidence rates of ovarian tumors in Indian registries are 
illustrated in table 11 and graph 7. 
 
 
COMPARISON OF INCIDENCE RATES IN INDIAN REGISTRIES 
Table 11 
 
Place of Study Incidence 
Delhi 8.5% 
Mumbai 6.5% 
Chennai 5.4% 
Mizoram 2.3% 
Present study 8.05% 
 
                                                           
                                                       
                                                    Graph 7 
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The incidence of ovarian malignant neoplasms among other gynaecological  
malignancies  in this study period was 8.05%.This ranks next to Delhi, 
where the incidence was 8.5%. Mizoram has the lowest incidence 2.3% 
12
 
 These observations suggest that the possible environmental and life 
style factors have an influence on the incidence rate. Hence in urban areas 
like Mumbai, changes in life style factors such as increase in age of 
marriage, delay in age at first birth, reduction in parity and improved 
socioeconomic conditions might have contributed to the increase in 
incidence in contrast with the rural area like Mizoram with the lower 
incidence. 
         As per the present study, ovarian carcinoma is the second most 
common gynaecologic malignancy in females (8.05%) next to cancer cervix 
(67%)(table 12) 
                                                        Table 12  
S.No. Site 
No. of 
malignancies 
% 
1. Cervix  593 67.23 
2. Ovary 71 8.05 
3. Endometrium  41 4.64 
4. Vulva 8 0.91 
5. Vagina 1 0.11 
6. Fallopian tube 0 0.11 
AGE INCIDENCE OF OVARIAN TUMORS: 
No age group was exempted from the occurrence of ovarian tumors 
including childhood. In the present study the majority of benign tumors 
occurred in the age group of  21-30 years (79.5%). This is in accordance 
with the studies conducted by Ramachandran et al (1972)
93
 and 
Jagadeeshwari N et al (1971)
43
. Majority of the malignant neoplasms 
occurred in the age group of 41-50 years in our study, which goes in hand 
with studies conducted by Jegadeeshwari N et al (1971)
43
 and Jha R and 
Karki S
49
, but in contrast with the study conducted by Ramachandran et al 
(1972)
99
 wherein, the maximum malignant tumors occurred in age group 
between 31-40 years. 
                       Table 13 Comparison of age in other studies 
 
Age (group) in years 
S.No. Authors < 
20yrs 
21-
30yrs 
31-
40yrs 
41-
50yrs 
51-
60yrs 
>60 
1. Tyagi SP 
70
 7.5 40.09 28.34 20.00 3.33 0.83 
2. Ramachandran 
et al 
5
 
11.57 26.24 21.37 22.70 12.29 4.53 
3. Saxena et al 
3
 10.67 31.17 27.52 20.25 6.75 3.65 
4. Present study 7.5 19.5 23 28 14.5 7.5 
Benign tumor cases had lower mean age and borderline tumor cases had 
higher mean age. But the difference was not statistically significant. 
 As per the literature and studies conducted by various authors, 
borderline forms are detected after the age of 40 years and 30-40% of them 
after the age of 68 years 
82
. In contrast, in our study borderline tumors stand 
in peak at the 3
rd
 decade.  
 
CLINICAL FEATURES OF OVARIAN TUMORS:  
 The following table shows the occurrence of clinical features in the 
different studies in comparison with the present study.  
                                           Table 14 
Sl. 
No. 
Clinical Features Gupta et al
33
 Couta F et al 
21
 Present 
Study 
1. Pain in lower 
abdomen 
46.2% 39.25% 50.2% 
2. Mass per abdomen 60.5% 90.20% 58.5% 
3. Menstrual 
disturbances 
40.2% 31.70% 5% 
4. Others (Pressure 
symptoms)  
34.5% 39.08% 3% 
 
 According to the studies of Gupta et al, the most common clinical 
feature was mass per abdomen which goes in accordance with our present 
study.  
 As per literature, menstrual irregularities were seen in 40.2% of cases 
(Gupta et al) whereas in our study only 5% of cases had similar symptoms.  
 
 
 CONSISTENCY OF OVARIAN TUMORS: 
 Table 15 comparison of   Consistency  of benign tumors with other 
studies 
Study Cystic Solid Mixed 
Jagadeeswari N  et al
79
 97.4 2.4 - 
Gupta et al 
33
 76.2 2.4 21.5 
Kapas MM pal NC
 51
 82.0 - 18 
Chhanda met al 
72
 30.8 - 69.2 
Present Study 6.2% 81.5% 12.3% 
 
Table16 comparison of   Consistency  of malignant tumors with other 
studies 
Study Cystic Solid Mixed 
Jagadeeswari N 
91
 et al 111 2.4 - 
Gupta et al 
73
  2.4 21.5 
Kapas MM pal NC
196
  - 18 
Chhanda met al 
72
  - 69.2 
Present Study  81.5% 12.3% 
 .   Various studies have shown that benign tumors are most often 
cystic in consistency while malignant tumors tend to be mixed (solid & 
cystic) or solid in consistency. This scenario has also been found in the 
present study 
LATERALITY OF OVARIAN TUMORS: 
 Table 17   Comparison of laterality of benign ovarian tumors 
Study Unilateral (%) Bilateral (%) 
Pilli et al 
74
 92.2% 7.8% 
Jha R & Karki S 
49
 93.3% 6.67% 
Present Study 90.3% 9.7% 
 
 Table 18 Comparison of laterality of malignant ovarian tumors 
Study Unilateral (%) Bilateral (%) 
Prabhakar & Maingi 
76
 78.10% 21.9% 
Misra RK et al (1991) 
67
 82.98% 17.2% 
Couto et al (1993) 
13
 72.4% 27.6% 
Present Study 64.6% 35.4% 
 
                   In our present study 90.3% of benign ovarian tumors were 
unilateral and 64.6% of malignant ovarian tumors were unilateral, whereas 
9.7% of benign ovarian tumors were bilateral and 35.4% of malignant 
ovarian tumors were bilateral. These findings imply that bilaterality is more 
common in malignant tumors. This is in accordance with the findings of 
other studies.  
 According to the literature, bilaterality is more common in serous than 
mucinous tumors, which goes in accordance with the present study.  
   
HISTOLOGICAL TYPES OF OVARIAN TUMORS: 
SURFACE EPITHELIAL TUMORS 
 In our study , Surface epithelial tumor stands as the most common 
ovarian neoplasm (155/200 cases – 77.5%) followed by germ cell tumors 
(22/200 cases – 11%)  , sex cord stromal tumors (15/200 cases – 7.5%)  and 
metastatic tumors (3/200 cases – 1.5%).  
 Of the surface epithelial tumors, serous epithelial tumors contribute 
61.2% and mucinous epithelial tumors contribute 36.20%.  
 These findings are in accordance with the literature. In the study  by 
katsube et al, koonings et al 
80
 and Petterson et al, mucinous borderline 
tumors are less common than serous borderline tumors but in our study 
mucinous borderline tumors out number the serous borderline tumors in 
close correlation with the studies by Isarangkul in Thailand. 
 Brenner tumors are often associated with other tumors such as 
mucinous cystadenoma, mature cystic teratoma and transitional cell 
carcinoma of  
bladder 
28
,
62
 .In our study 2 such associations with benign mucinous 
cystadenoma has been observed(fig18).  Association may be due to 
overgrowth of metaplastic mucinous epithelium. 
          Other associations with mucinous cystadenoma commonly seen were 
with teratoma (4-5%)and carcinoid tumor. 
  One case of bilateral malignant Brenner tumor was observed in a 65 year 
old female who presented with abdominal mass. Grossly the tumor measured 
10x8x5 cm and 4x3x2 cm on each side( fig7). The tumor was arranged in 
sheets with stromal invasion.(fig 20) 
GERM CELL TUMORS 
Dysgerminoma :  
  Three cases were diagnosed as dysgerminoma which accounted for 
1.5% of all the tumors in the present study ( fig41). This was the third most 
common malignant germ cell tumor in our study in contrast to studies 
conducted by Kurman RJ et al, Bjorkholm et al and Mankad MH et al 
55 
wherein, dysgerminoma was the most common.  
Yolksac tumor:  
 Yolk sac tumor  was seen in 4 patients accounting for 2% of all 
ovarian tumors. Krigman et al highlighted the fact that this was the second 
commonest type of malignant germ cell tumor of the ovary with a median 
age of 19 years
54
. Which is in accordance  with our study.  
 Microscopically tumor cells were arranged in  microcystic reticulated 
pattern.  PAS positive, diastase resistant intra and extra cellular hyaline 
globules and Schiller – duval bodies were seen (fig 28). Kurman et al
55
 
observed that though reticular pattern is the common type, festoon pattern 
with Schiller – duval bodies was the easiest to identify.  
3) Teratoma 
 This was the commonest germ cell tumor found in the present study 
constituting 7.5% of all the tumors. All were benign cystic teratomas ( fig 
29) except one immature teratoma. These findings were similar to those 
observed by Sahn L et al, Gupta SC et al and Couto F et al.
13
 
One case of unilateral immature teratoma grade II tumor was observed in a 
12 year girl who presented with mass per abdomen, tumor measuring 
13x10x5 cm, cut surface was  solid & cystic. Microscopically showed 
tissues derived from all germ cell layers and immature neuroectodermal 
elements ( Fig 30).  
 We encountered a relatively rare association of adenocarcinoma occuring as 
a secondary malignancy in Benign cystic teratoma in a 45 year female.         
          Two cases of mixed epithelial tumors were observed. Combinations of 
mucinous cystadenoma of ovary with benign Brenner tumor was observed in 
the same ovary in both cases (fig.18). 
SEX – CORD STROMAL TUMORS 
 Granulosa cell tumor is the commonest sex cord stromal tumor. 
Further it is also the commonest functional ovarian tumor with hormone 
(oestrogen) production.  In the present study 8 cases (4%) were reported as 
granulosa cell tumor.   
Tyagi SP, Tyagi GK and logani KP found an incidence of 3.3% in a 
pathological study of 120 cases
 60
.  Jagadeswari N, Reddy RS and Rao
78
 
found an incidence of 3.7% while Ramachandran G et al
 77 
found an 
incidence of 2.7% as shown in table.  
 Table 19 Incidence of Granulosa Cell Tumors In Different Studies 
S.No. Authors Incidence (%) 
1. Tyagi SP et al 104 3.30 
2. Jagadeswari et al 107 3.70 
3. Ramachandran G et al 106 2.70 
4. Gupta SC et al  4.40 
5. Present Study  4.0 
  
        The commonest presenting symptom in the granulosa cell tumor was 
menorrhagia, similar symptom was encountered by Stenwit JT et al
93
, while 
this was the second commonest symptom in the study by Pancratz E et al 
26
.  
Microscopy:  
 Microscopically a mixture of microfollicular, trabecular and diffuse 
patterns were seen along with typical  Call-Exner bodies( Fig 21). Though 
Stenwing et al
39
 observed that these characteristic bodies were found only in 
60% of the cases. Well differentiated tumor has a longitudinal nuclear 
groove. Presence of 3 or more mitosis / 10HPF and degree of cellular atypia 
correlated with a worst prognosis in the study by Stenwing was JT et al
83
. In 
this study, we applied reticulin stain for granulosa cell tumors and 
fibrothecoma. The stain shows fibrils surrounding the nests and large 
aggregates of granulosa cells(fig.24). In thecoma reticulin stain highlights an 
investment of individual cells by fibrils.   
2) Fibroma: 
 2.35% of all tumors were fibromas in the studies by Gupta SC et al
73
. 
These percentage was higher than 1% in the present study.  
3) Fibrothecoma:  
 According to the Evan AT et al, the peak age of occurrence was 51–
60 yrs. This goes in accordance with the present study wherein the mean age 
incidence was 50.2 years. Cut section of the tumor was solid grey – yellow,  
this feature according to Evans AT et al. helps to distinguish grossly, 
thecoma from fibroma which have greyish white appearance 
26
.  
METASTATIC TUMORS 
 Three cases of Krukenberg tumor were found among the 200 cases of 
ovarian tumors( fig 32). This was lower than study reports by Holt ZF and 
Hart WR (1982) (3-5%). 
39 
 
 PAS stain is an extremely useful and aesthetically pleasing technique.  
In our study mucinous carcinoma of ovary shows PAS positive mucin pools 
( fig 34), and Krukenberg tumor show intracellular PAS positivity(fig 33). In 
a study by Powari M et al
75
, out of 19 metastatic tumors, 31.5% (6 cases) 
were Krukenberg tumors. The incidence is much higher compared to the 
present study.    
IMPORTANCE OF IMMUNOHISTOCHEMICAL CONFIRMATION 
IN GRANULOSA CELL TUMORS: 
           During the study period ,out of 200 cases  10 were  
histopathologically diagnosed as granulosa cell tumor. We did 
immunohistochemical marker study in all these cases for confirmation. 
Surprisingly,in one case  tumor cells showed strong expression of 
chromogranin and synaptophysin and negative for vimentin.. Final diagnosis 
of ovarian Carcinoid was made. 
       On retrospective analysis, no other tumor mass was detected elsewhere 
by abdominal ultrasonography and CT scan,  Isolated Tricuspid 
regurgitation was incidentally found in preoperative echocardiography. 
        In correlation with the above findings , we came to conclusion of 
Primary ovarian Carcinoid tumor with  isolated Tricuspid regurgitation. 
          And in another case Vimentin and Inhibin were negative and EMA 
was positive. And so the final diagnosis of poorly differentiated carcinoma 
was made. The significance of differentiating Granulosa cell tumor and 
poorly differentiated carcinoma lies in the fact that the treatment modalities 
of both these tumors vary markedly. Granulosa cell tumor is a benign in 
which case total abdominal hysterectomy with bilateral salphingo 
oopherectomy (TAH-BSO) alone would suffice whereas in a case of poorly 
differentiated tumors of ovary along with TAH-BSO, chemotherapy is 
mandatory. 
            The remaining  8 cases  showed vimentin  positivity  and  were 
negative for EMA.  These tumors were diagnosed as  Granulosa cell tumors .      
                   Thus Immunohistochemical confirmation is always necessary in 
Granulosa cell tumors to rule out other differential diagnosis which simulate 
them histopathologically. This is very important because treatment protocol 
varies for each. 
Ki-67 LABELLING INDEX : 
 
            The rate at which a tumor proliferates has long been considered to 
bear a relationship with its clinical course. The determination of growth 
fraction using Ki- 67 index is a simple method and has long been shown to 
have a prognostic value in a variety of malignancies like CNS tumors, 
Lymphoproliferative diseases, connective tissue tumors and breast tumors 
69
. 
Ki67 expression in different ovarian tumors has long been studied by various 
authors across the world. However , there is a paucity of such a study  in the 
Indian literature.  Few  literature clearly document the importance of  Ki 67 
proliferative marker in assessing the prognosis  of ovarian cancers. 
  We  evaluated Ki 67 expression in 24 selected cases  which included 4 
benign cystadenoma(2 serous,2 mucinous), ,4 borderline cystadenomas (2 
serous,2 mucinous),4 carcinoma (2 serous, 2 mucinous adenocarcinoma), 2 
Germ cell tumors, 8 granulosa cell tumors. 
 
1 ) Ki 67 INDEX  IN BENIGN , BORDERLINE  AND MALIGNANT OVARIAN 
TUMORS: 
            The Ki 67 index gradually increase from benign to malignant tumors
 
69
. We observed the same in our study with ki-67marker. 
Benign tumors had a mean Ki 67index of  2.9% , borderline tumors had a 
mean  Ki 67 index of  7.2%  ,while the malignant tumors had a mean Ki 67 
index of 29.9% . 
          A statistically significant difference (p =<0.001) was obtained 
between the mean Ki 67 indices of benign, borderline & malignant tumors. 
These findings are in close agreement with Garzetti et al 
29
 and with 
Monisha chowdhury et al
.69
 
           Ki 67 index is especially useful in borderline epithelial ovarian 
tumors of low malignant potential. These are seen in younger premenopausal 
women between 30-50 years of age. They remain confined to ovary for a 
longer time. Overall about 15-25 % of borderline tumors behave in a 
malignant fashion,  invading  locally and even  metastasizing. It is thus 
important to identify those borderline neoplasms which are likely to behave 
in a malignant fashion, for it is possible that histological grading of the 
degree of  severity of the epithelial proliferation and atypia may prove to 
have some prognostic benefits
.7
 
 
b) Ki 67 INDEX  IN  GRANULOSA CELL TUMORS: 
                
          Granulosa cell tumors behave unpredictably. Histopathologic 
evaluation of Granulosa cell tumors offers only few clues.
. 
It is difficult to 
predict their prognosis by pathologic means. Tumors larger than 15 cm, 
bilateral tumors, spread beyond ovary(FIGO stage >1A) or ruptured have 
less favourable prognosis. The ‘stage’ is the single most powerful prognostic 
indicator 
17
  .  
           Ki 67 index provide insight into nuclear proliferation and to predict 
the clinical behavior of Granulosa cell tumors
19
.  
     In this study Ki 67immunohistochemistry was assessed in all the 
Granulosa cell tumors (8 cases) and the results were correlated with tumor 
stage at presentation.             Mean Ki 67 index for 8 cases of histologically 
and immunohistochemically proven case of granulosa cell tumor was 
5.1%.(fig 44). 
 In the present study , Ki 67 index was higher in  2 cases of. Granulosa cell 
tumors (7.9% and 8.4%) which correlated clinically with higher stage (FIGO 
stage I(c) disease).This is in correlation with the study conducted by Costa 
MJ,Walls J et al 
19 
who also proved that higher Ki 67 index  in GCT was associated with worst 
prognosis. 
    Ki 67 index in the rest of the Granulosa cell tumors was low which 
correlated clinically with FIGO stage I(a) disease. This goes in hand with 
study conducted by Costa MJ,Walls J et al 
19 
who also proved that lower Ki 
67 index in GCT was associated with better prognosis.      
    Thus in the present study, ki 67 index was higher in advanced stage 
tumors, and thereby pointing toward the aggressive clinical behavior  and  
poorer clinical outcomes.
 
Even though Granulosa cell tumor usually has good prognosis, it is a tumor 
of unquestionable malignant potential and has a tendency for late relapse. 
Case series  and reports suggest that post operative chemotherapy is of most 
benefit in advanced diseases  and  long term follow-up is recommended.
100-
102 
OVARIAN CANCER WITH ASSOCIATED ENDOMETRIAL 
CANCER: 
 
            The simultaneous development of multiple primary cancers in the 
upper female genital tract is a well known phenomenon. Of these the 
commonest is the endometrioid carcinoma of the ovary and the uterus. 
Diagnosis of this type of tumor either as a separate independent primary or 
as a metastatic tumor is difficult. A careful consideration of a number of 
gross, histological and immunohistochemical features may be helpful in the 
distinction between metastatic and synchronous primary tumors   which 
have different therapeutic and prognostic  implications 
45,104,68 
    Out of 200 ovarian tumors, 5 were associated with endometrial carcinoma 
(2.5%).Among those 5cases, 3 showed the same histologic pattern in both 
ovary and endometrium. One was bilateral mucinous cystadenoma with 
endometrioid type of endometrial adenocarcinoma. Other case was ovarian 
Granulosa cell tumor with endometrial adenocarcinoma.It is due to estradiol 
overproduction which continuously stimulates endometrium. Endometrial 
cancer occurs in association with Granulosa cell tumor in atleast 5% of 
cancer and 25% to 50 % are associated with endometrial hyperplasia.
7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Summary  
 
 
SUMMARY 
 
 In the present prospective study of 200 ovarian neoplasms evaluated 
with clinical, histopathological, histochemistry and immunohistochemistry, 
the following conclusions are made.  
1. The incidence of ovarian neoplasms  was 8.05% and ranked second 
among the malignancies of female genital tract. 
2. The incidence of ovarian neoplasms wass highest during the 5th 
decade. The peak age incidence of  benign tumors was 3
rd
 decade and 
that for  borderline  and malignant tumors was 4
th
  and 5
th
 decade 
respectively.  
3. The most common symptom was mass per abdomen (58%), followed 
by pain (51%) and menstrual disturbances(5%).  
4. 81.5% of ovarian tumors were unilateral and 18.5%were bilateral. 
5. 85.5% of benign tumors were predominantly cystic and 81.5% of 
malignant tumors were predominantly solid and cystic or purely solid. 
6. The size of the ovarian tumors varied from  2 to 30 cm . 
7. 77.5% were Surface Epithelial tumors, 7.5% were Sex Cord Stromal 
tumors, 11% were Germ Cell tumors, 1.5% were metastatic tumors 
and 2.5% were  undifferentiated tumors. 
8. .In Surface epithelial tumors, benign serous cystadenoma was the 
most common (25%). 
9. In Sexcord stomal tumors, Granulosa cell tumor was the most 
common( 5%). 
10. In Germ cell tumors, benign cystic Teratoma was the most 
common(7.5). 
11. 62% of ovarian tumors were benign, 5.5% were borderline and 32.5% 
were malignant. 
12. Reticulin stain plays a vital role in distinguishing between 
Fibrothecoma and Granulosa cell tumor. PAS stain is used to 
differentiate between krukenberg tumor and mucinous cystadeno 
carcinoma.  
13. In this study, 2 cases which were histolopathologically diagnosed as 
ovarian granulosa cell tumor was finally diagnosed as Primary ovarian  
Carcinoid tumor and Poorly differentiated carcinoma respectively 
after immunohistochemical study.  
14. Benign ovarian tumors had a mean Ki 67 index of      2.9%, 
borderline tumors had a mean Ki- 67 index of 7.2%, while the 
malignant tumors had a mean Ki 67  index of 29.9%. 
        The difference in the mean value between benign, borderline, and      
malignant epithelial tumors  were statistically significant (p =<0.001). 
15.  In Granulosa cell tumors, the mean Ki 67 index was 5.1%. (fig 44) and 
it was  higher in two cases with higher clinical stage. 
16. Several interesting cases which  we encountered were   
A. Two cases of mixed epithelial tumors composed of 
mucinouscystadenoma of ovary and benign Brenner tumor (fig 18) 
B. One case of bilateral malignant Brenner tumor  in a 65 yearold female 
(fig 20 
C. One case of juvenile granulosa cell tumor in a 2 year old girl with 
precocious puberty (fig 22) 
D. A case of unilateral granulosa cell tumor associated with  well 
differentiated endometrial adenocarcinoma and omental metastatic 
deposits. 
E. A rare association of adenocarcinoma occuring as a secondary 
malignancy in Benign cystic teratoma .  
F. One case of immature teratoma with  neuroectodermal elements . 
G. 2.5% (5 cases) ovarian tumors were associated with endometrial 
carcinoma.  
                                           
      
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                   
 
 
Conclusion   
 
 
CONCLUSION 
 
 Accurate diagnosis of ovarian tumors can be rendered in most of the 
cases by correlating the clinical presentation, gross and microscopic features. 
Histochemistry and immunohistochemistry are  essential in certain ovarian 
tumors with doubtful diagnosis. In our study , immunohistochemical 
markers were very useful in accurate diagnosis of Granulosa cell tumors. 
            Ki 67 immunostaining is a simple method which provides robust 
prognostic information for patients with ovarian cancers. This biomarker is 
very much useful to identify borderline tumors which are likely to behave in 
a malignant fashion,to assess the prognosis in Granulosa cell tumors  and 
may define subgroups of patients who would  be more likely to benefit  from 
cell- cycle dependent chemotherapy regimens, and may guide the 
development of future therapeutic strategies. 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Annexure – I  
 
 
 
 
 
 
 
 
 PROFORMA 
Name   :  
Age   : 
IP.No / Unit  : 
Biopsy  No.  : 
Clinical Features  : Pain / Mass Abdomen / Acute Abdomen / 
Menstrual  
Irregularity  
Clinical Diagnosis : 
Gross   : 
Laterality   :  Unilateral / Bilateral 
Size    :   
Consistency Cystic :  Solid / Solid & Cystic 
Microscopy  :  
1. Tumor differentiation :  Benign / Borderline / Malignant 
2. Histological Types  : Surface Epithelial / sexcord stromal I Germ 
Cell 
3. Subtypes   : 
Metastasis   : 
IHC / Special Stain/ Ki67 index   :  
Clinical & Histological Correlation  : 
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PROCEDURES 
HEMATOXYLIN AND EOSIN 
1. Bring the sections to water. 
2. Stain in Harris Hematoxylin for 5 minutes 
3. Wash well in tap water 
4. Differentiate in 1% acid alcohol 
5. Wash in running tap water for 10-15 minutes 
6. Stain in 1% eosin for 1 to 2 minutes 
7. Wash in  tap water for 1 to 5 minutes 
Dehydrate with alcohol, clear  in Xylene and mount in DPX.  
SPECIAL STAINS 
PERIODIC ACID SCHIFF STAIN: modified McMannus 1946 
 
Periodic acid solution 
 
Periodic acid       : 1 gm 
Distilled water     : 100 ml 
 
PREPARATION OF SCHIFF REAGENT 
 
Dissolve 1gm of basic fuchsin and 1.9gm of sodium metabisulfite in 100ml of 
0.15N Hydrochloric acid. Shake the solution at intervals, until it is clear and 
yellow to light brown in colour. Add 500mg of activated charcoal and shake for 1 
to 2 mins. Filter the solution  through a No.1 Whatman filter. The filtered solution 
should be clear and colourless. Store at 4 degree  centigrade. 
Method: 
1. Bring the sections to water 
2. Treat with periodic acid for 5 minutes  
3. Wash well with several changes of distilled water 
4. Cover with schiff’s reagent for 15 minutes 
5. Wash in running tap water 5-10 minutes 
6. Stain nuclei with Harris Hematoxylin. Differentiate in acid alcohol 
and blueing in tapwater  for 5 minutes. 
7. Wash in water 
8. Rinse in absolute alcohol 
9. Clear in Xylene and mount with DPX 
 
RESULTS 
      Glycogen  :  Magenta 
Nuclei  : Blue 
RETICULIN STAIN ( GOMORI’S METHOD) 
Preparation of silver solution:  
                To 10ml of 10% potassium hydroxide solution add 40ml of 10% 
silver nitrate solution. Allow the precipitate to settle and decant the 
supernatant. Wash the precipitate several times with distilled water. Add 
ammonia drop by drop until the precipitate has just dissolved. Add further 
10% silver nitrate solution until a little precipitate remains. Dilute to 100 ml 
and filter. Store in a dark bottle.  
Method:  
1. Deparaffinize sections and bring to water.  
2. Treat with 1% potassium permanganate solution, 2 minutes.  
3. Rinse in tap water.  
4. Bleach in 2% potassium metabisulfate solution.  
5. Rinse in tap water.  
6. Treat with 2% iron alum, 2 minutes.  
7. Wash in several changes of distilled water.  
8. Place in Coplin jar of silver solution, 1 minute.  
9. Wash in several changes of distilled water.  
10. Reduce in 4% aqueous formalin solution, 3 minutes.  
11. Rinse in tap water.  
12. Tone in 0.2% gold chloride solution, 10 minutes. 
13. Rinse in tap water.  
14. Treat with 2% potassium metabisulfite solution, 1 minute. 
15. Rinse in tap water.  
16. Treat with 2% sodium thiosulfate solution, 1 minute. 
17. Rinse in tap water.  
18. Counterstain as desired ( Van Gieson or eosin is suitable.)  
19. Dehydrate  
20. Clear in xylene and mount in permanent mounting medium. 
Results:  
 Reticular fibers black 
 Nuclei Gray 
 Other tissues according to counterstain 
 
IMMUNOHISTOCHEMISTRY: 
                  An assay that shows specific antigens in tissues by the use of 
markers that are either fluorescent dyes or enzymes 
(such as horseradish peroxidase) 
 
   Visualising an antibody-antigen interaction can be accomplished in a 
number of ways. 
 
      Immunoperoxidase staining an antibody is conjugated to an enzyme, 
such as peroxidase, that can catalyse a colour-producing reaction. 
    Immunofluorescence staining: the antibody can also be tagged to a 
fluorophore, such as FITC, rhodamine, Texas Red, Alexa Fluor, or DyLight . 
 
Sample preparation 
In the procedure, either thin (about 4-40 µm) slices are taken of the tissue of 
interest, or if the tissue is not very thick and is penetrable it is used whole.  
 Direct and indirect IHC 
DIRECT METHOD      : One labelled antibody, which binds directly to the  
antigen being stained  for   
 INDIRECT METHOD : One antibody against the antigen being probed for,  
and a second, labelled, antibody against the first    
In a common procedure, a biotinylated secondary antibody is coupled with 
streptavidin-horseradish peroxidase. This is reacted with 3,3'-
Diaminobenzidine (DAB) to produce a brown staining wherever primary 
and secondary antibodies are attached in a process known as DAB staining. 
The reaction can be enhanced using nickel, producing a deep purple/gray 
staining. 
 
 
.      DIRECT METHOD                                    INDIRECT METHOD 
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WHO CLASSIFICATION OF OVARIAN TUMORS 
Surface epithelial-stromal tumors 
Serous tumors 
 Malignant 
  Adenocarcinoma 
  Surface papillary  Adenocarcinoma 
  Adencarcinofibroma(malignant adenofibroma) 
 Borderline tumor 
  Papillary cystic tumor 
  Surface papillary tumor 
  Adenofibroma,cystadenofibroma 
 Benign 
  Cystadenoma 
  Papillary cystadenoma 
  Surface papilloma 
  Adenofibroma and cystadenofibroma 
Mucinous tumors 
 Malignant 
  Adenocarcinoma 
  Adenocarcinofibroma (malignant adenofibroma) 
Borderline tumor 
  Intestinal type 
  Endocervical – like 
Benign 
  Cystadenoma 
  Adenofibroma and cystadenofibroma 
 Mucinous cystic tumor with mural nodules 
 Mucinous cystic tumor with pseudomyxoma peritonei 
 
Endometrioid tumors including variants with squamous differentiation 
 
 Malignant 
  Adenocarcinoma not otherwise specified 
  Adenocarcinofibroma (malignant adenofibroma) 
  Malignant mullerian mixed tumor 
  (carcinosarcoma) 
  Adenosarcoma 
  Endometrioid stromal sarcoma (low grade) 
  Undifferentiated ovarian sarcoma 
 
 Borderline tumor 
  Cystic tumor 
  Adenofibroma and cystadenofibroma 
 Benign 
  Cystadenoma 
  Adenofibroma and cystadenofibroma 
Clear cell tumors 
 
 Malignant 
  Adenocarcinoma 
  Adenocarcinofibroma (malignant adenofibroma) 
 Borderlinetumor 
  Cystic tumor 
  Adenofibroma and cystedenofibroma 
 Benign 
  Cystadenoma 
  Adenofibroma and cystadenofibroma 
Transitional cell tumors 
 Malignant 
  Transitional cell carcinoma (non-Brenner type) 
  Malignant Brenner tumor 
 Borderline 
  Borderline Brenner tumor 
  Proliferating variant 
 Benign 
  Brenner tumor 
Metaplastic variant 
Squamous cell tumors 
  Squamous cell carcinoma 
  Epidermoid cyst 
Mixed epithelial tumors (specify components) 
  Malignant 
  Borderline 
  Benign 
Undifferentiated and unclassified tumors 
  Undifferentiated carcinoma 
  Adenocercinoma,not otherwise specified 
Sex cord-stromal tumors 
Granulosa -stromal cell tumors 
 Granulosa-stromal cell tumor group 
  Adult granulosa cell tumor 
  Juvenile granulosa cell tumor 
 Thecoma-fibroma group 
  Thecoma,not otherwise specified 
   Typical 
   Luteinized 
  Fibroma 
  Cellular fibroma 
  Fibrosarcoma 
  Stromal tumor with minor sex cord elements 
  Sclerosing stromal tumor 
  Signet-ring stromal tumor 
  Unclassified (fibrothecoma) 
Sertoli-stromal cell tumors 
 Sertoli – Leydig cell tumor group (androblastomas) 
  Well differentiated 
  Of intermediate differentiation 
   Variant with heterologous elements(specify type) 
  Poorly differentiated (sarcomatoid) 
   Variant with heterologous elements (specify type) 
  Retiform 
   Variant with heterologous elements (specify type) 
 Sertoli cell tumor 
 Stromal-Leydig cell tumor 
Sex cord-stromal tumors of mixed or unclassified cell type 
 Sex cord tumor with annular tubules 
 Gynandroblastoma (specify components) 
 Sex cord-stromal tumor,unclassified 
 
 
Steroid cell tumors 
  Stromal luteoma 
 Leydig cell tumor group 
  Hilus cell tumor 
  Leydig cell tumor,non-bilar type 
  Leydig cell tumor,not otherwise specified 
 Steroid cell tumor,not otherwise specified 
  Well differentiated 
  Malignant 
 
Germ cell tumors 
Primitive germ cell tumors 
 Dysgerminoma 
 Yolk sac tumor 
  Polyvesicular vitelline tumor 
  Glandular variant 
  Hepatoid variant 
 Embryonal carcinoma 
  Polyembryoma 
  Non-gestational choriocarcinoma 
  Mixed germ cell tumor (specify components) 
 Biphasic or triphasic teratoma 
  Immature teratoma 
  Mature teratoma 
   Solid 
   Cystic 
    Dermoid cyst 
   Fetiform teratoma (homunculus) 
 Monodermal teratoma and somatic-type tumors associated 
 With dermoid cysts 
  Thyroid tumor group 
   Struma ovarii 
    Benign 
    Malignant (specify type) 
 
  Carcinoid group 
   Insular 
   Trabecular 
   Mucinous 
   Strumal carcinoid 
   Mixed 
  Neuroectodermal tumor group 
   Ependymoma 
   Primitive neuroectodermal tumor 
   Medulloepithelioma 
   Glioblastoma multiforme 
   Others 
  Melanocytic group 
   Malignant melanoma 
   Melanocytic naevus 
  Sarcoma group (specify type) 
  Sebaceous tumor group 
   Sebaceous adenoma 
   Sebaceous carcinoma 
  Pituitary –type tumor group 
  Retinal anlage tumor group 
  Others 
 Germ cell sex cord-stromal tumors 
  Gonadoblastoma  
   Variant with malignant germ cell tumor 
  Mixed germ cell-sex cord-stromal tumor 
   Variant with malignant germ cell tumor 
 Tumors of  the rete ovarii 
   Adenocarcinoma 
   Adenoma 
   Cystadenoma 
   Cystedenofibroma 
 
 Miscellaneous tumors 
   Small cell carcinoma,hypercalcemic type 
   Small cell carcinoma,pulmonary type 
   Large cell neuroendocrine carcinoma 
   Hepatoid carcinoma 
   Primary ovarian mesothelioma 
   Wilms tumor 
   Gestational choriocarcinoma 
   Hydatidiform mole 
   Adenoid cystic carcinoma  
   Basal cell tumor 
   Ovarian wolffian tumor 
   Paraganglioma 
   Myxoma  
   Soft tissue tumors not specific to the ovary 
   Others 
 Tumor-like conditions 
   Luteoma of pregnancy 
   Stromal hyperthecosis 
   Stromal hyperplasia 
   Fibromatosis 
   Massive ovarian oedema 
   Others 
 Lymphoid and haematopoetic tumors 
   Malignant lymphoma (specify type) 
 
 
 
   Leukaemia (specify type) 
   Plasmacytoma 
 Secondary tumors 
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ABSTRACT 
 
BACKGROUND AND OBJECTIVES 
                    The ovarian tumors manifest a wide spectrum of clinical, 
morphological and histological features. Their complex nature, unpredictable 
behaviour, prognosis and varying therapeutic strategies, necessitates an accurate 
diagnosis. 
                   Hence this study was undertaken to correlate the clinical and 
pathological parameters and to analyse the role of Ki 67, a nuclear protein 
expressed by mitotic cells, as a prognostic marker in ovarian tumors and also to 
evaluate the usefulness of immunohistochemical markers for confirmatory 
diagnosis of Granulosa cell tumors. 
 
METHODS 
                   This study was done in the Department of Pathology, Madurai Medical 
College, Madurai, for a period of two years (2009-2011), on 200 ovarian 
neoplasms out of 239 ovarian lesions received after exclusion of non-neoplastic 
lesions. A detailed history regarding the clinical symptoms and signs were 
recorded. Representative bits were processed and stained with hematoxylin and 
eosin . Special stains like PAS, reticulin were done in selected cases. 
                     Immunostaining was performed on 24 selected cases with 
proliferative marker Ki 67 using peroxidase-antiperoxidase technique and 
immunohistochemical marker study was done in all cases of Granulosa cell tumors 
with vimentin ,inhibin and for selected cases with chromogranin and EMA. 
 
 
 
 
RESULTS 
                        The incidence of ovarian neoplasms was 8.05% and ranked second 
among the female genital tract malignancies. The peak age incidence was fifth 
decade. Mass per abdomen was the most common clinical presentation (58%). 
81.5% were unilateral and 18.5% were bilateral. Surface epithelial tumors were the 
commonest (77.5%), sex cord stromal tumors 7.5% and germ cell tumors 11%. Out 
of 200 cases, benign tumors constituted 62%, borderline tumors constituted 5.5% 
and malignant tumors 32.5%. There were 3 cases (1.5%) of Krukenberg’s tumor. 
The difference in the mean     Ki 67 index between benign (2.9%), borderline 
(7.2%) and malignant tumors (29.9%) was statistically significant. In Granulosa 
cell tumors the mean Ki 67 index was 5.1% and it was higher in two cases with 
higher clinical stage. 
 In this study, two cases which were histopathologically diagnosed as Granulosa 
cell tumors were finally diagnosed as Primary ovarian carcinoid tumor and Poorly 
differentiated carcinoma respectively after immunohistochemical study.  
 
 
CONCLUSION 
              Accurate diagnosis of ovarian tumors can be rendered in most of the cases 
by correlating the clinical and pathological parameters. Immunohistochemistry is 
essential in Granulosa cell tumors with doubtful diagnosis. Ki 67 immunostaining 
provides robust prognostic information and is very much useful to identify 
borderline ovarian tumors which are likely to behave in a malignant fashion and 
also to assess the prognosis of Granulosa cell tumors. 
 
Key words: 
ovarian tumors, surface epithelial tumors, germ cell tumors,  granulosa cell tumors, 
immunoproliferative marker Ki 67. 
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1  G 2125/7/ 09 41357 26  A.MASS       P 3.5X2 X 0.5 P P P ASCITES  MUCINOUS CYSTADENOCARCINOMA
2 G 2151/7/09 57854 33 mass ABDOMEN  P  8 X 5X2 p P  DERMOID CYST
3 G 2258/7/09 53216 53 MASS P 11X9X6 P P  SEROUS PAPILLARY CYSTADENOCARCINOMA
4 G2259/7/09 41144 50 MASS P 9X5X4 P p  ASCITES PAPILLARY MUCINOUS CYSTADENOCARCINOMA
5 G2355/7/09 406606 63 MASS P 10X8X2 P P  BENIGN SEROUS  CYSTADENOMA
6 G2358/7/09 40610 43 mass ABDOMEN P 18X6X4 P P BENIGN MUCINOUS CYSTADENOMA
7 G2369/7/09 57490 23 MASS P 8X5X3 P P OMENTUM YOLK SAC TUMOR
8 G2402/7/09 57205 25 mass  ABDOMEN P 6X4X3 P P BENIGN SEROUS CYSTADENOMA
9 G2403/7/09 57228 48 MASS P 15 X5X3 P P BENIGN MUCINOUS CYSTADENOMA
10 G2437/7/09 40861 40 mass  ABDOMEN P 8X4X2 P P BENIGN SEROUS CYST
11 G2526/7/09 40483 40 MASS, PAIN P 7X6X2 P P PAPILLARY  SEROUS CYSTADENOCARCINOMA
12 G2527/7/09 40567 44 PAIN  P 8X5X3 P P BENIGN SEROUS CYSTADENOMA
13 G2539/7/09 41036 45 MASS P 7X5X2 P P BENIGN MUCINOUS CYSTADENOMA
14 G2540/8/09 O61709 50 PAIN, MASS P 6X4X2 P p MUCINOUS TUMOUR OF BORDERLINE MALIGNANCY
15 G2575/8/09 40821 50 MENSTRUAL DISTURBANCES P 8X6X2 P P  ENDOMETRIOID CARCINOMA OVARY
16 G2576/8/09  41063 40 MENSTRUAL DISTURBANCE P 16X10X6  P P BENIGN MUCINOUS CYSTADENOMA 
17 G2578/8/09  58721 50 MASS P 7X6X2 P P BENIGN MUCINOUS CYSTADENOMA
18 G2624/8/09 57129 40 MASS P 4X3X2  P P BENIGN SEROUS CYST
19 G2627/8/09 411 41182 21 MASS P 5x4x3 P P DYSGERMINOMA
20 G2636/8/09 40737 50 mass  ABDOMEN P 5X3X2 P P BENIGN SEROUS CYSTADENOMA
21 G2655/8/09 40862 32 massABDOMEN 4X3X2  P P BENIGN SEROUS CYST
22 G2715/8/09 40829 60 MASS P 18X16X7  P P MUCINOUS TUMOR OF BORDERLINE MALIGNANCY
23 G2725/8/09  62641 42 MASS P 10X6X4 P P BENIGN MUCINOUS CYSTADENOMA
24 G2726/8/09 41269 27 mass ABDOMEN P 6X5X3 P P BENIGN CYSTIC TERATOMA
25 G2767/8/09 41012 41 MASS 5X3X2 P P BENIGN MUCINOUS CYSTADENOMA
26 G2838/8/09 41227 29 PAIN P 6X3X1 P P BENIGN SEROUS CYST
27 G2840/8/09 41083 28 MASS PAIN  P 4X3X2  P P BENIGN SEROUS CYSTADENOMA
28 G2878/8/09 64258 60 MASS PAIN  P 10X6X2 P P PAPILLARY SEROUS CYSTADENOCARCINOMA
29 G2955/8/09 59862 60 MASS p 5x4x1 P p GRANULOSA CELL TUMOR  VIM + ,INH + 5.40%     Ia
30 G3024/9/09 41380 42 MASS P 14X10X6 P P BENIGN MUCINOUS CYSTADENOMA
31 G3059/9/09 73709 22 PAIN  P 10X7X2 P P BENIGHN  SEROUS CYSTADENOMA
32 G3070/9/09  70836 45 PAIN P 7X5X3 P P BENIGN   CYSTIC TERATOMA
33 G3072/9/09 70753 60 MASS P 6X3X2 P p FIBROTHECOMA
34 G3087/9/09 8809 32 MASS P 8X8X4 P P BENIGN SEROUS CYSTADENOMA
35 G3167/9/09 41490 27 MASS 6X4X2 P P BENIGN SEROUS CYSTADENOMA
36 G3242/9/09 51917 58 MASS, PAIN, MENSTRUAL DISTURP 7X6X5 p p
RIGHT‐ PAPILLARY CYSTADENOCARCINOMA, LEFT ‐ PAPILLARY SEROUS 
CYSTADENOCARCINOMA
37 G3359/9/09 77280 35 MASS P 10X8X6 P P ASCITES+ MUCINOUS CYSTADENOCARCINOMA
38 G3487/10/09 9656 47 MASS P 15X10X 3 P P BENIGN SEROUS CYSTADENOMA
39 G3429/10/09 41556 76 MASS P 15X13X6 P p FIBROTHECOMA
40 G3454/10/09 41712 60 mass  ABDOMEN P 5X4X2 ( BOTH) P P BENIGN MUCINOUS CYSTADENOMA
41 G3489/10/09 76007 46 MASS, PAIN P 12X8X2 P p PAPILLARY SEROUS CYSTADENOCARCINOMA
42 G3517/10/09 42003 55 PAIN P 18X10X3 P P BENIGN  SEROUS CYSTADENOMA
43 G3518/10/09 80421 25 MASS, PAIN P 8X3X2 P P BENIGN SEROUS CYSTADENOMA
44 G3520/10/09 75381 55 MASS P 8X5X2 P P PAPILLARY SEROUS CYSTADENOCARCINOMA
45 G3525/10/09 42088 67 MASS P 14X9X5 P P EM, MYO, AS SEROUS ADENOCARCINOMA
46 G3524/10/09 79818 21 MASS, PAIN P 25X15X3 P p MUCINOUS TUMOR OF BORDERLINE MALIGNANCY
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47 G3654/10/09 77726 1 MASS P 10X8X2 P P BENIGN SEROUS CYSTADENOMA
48 G3566/10/09 83217 50 MASS, PAIN P 4X3X0.5 P P PAPILLARY SEROUS ADENOCARCINOMA 
49 G3616/10/09 O42021 38 MASS, MENSTRUAL DISTUR P 8X5X2 P P BENIGN SEROUS CYSTADENOMA
50 G3659/10/09 81972 45 PAIN P 10X7X3 P P BENIGN MUCINOUS CYSTADENOMA
51 G3660/10/09 42294 35 PAIN P 15X10X3 P P BENIGN SEROUS CYSTADENOMA
52 G3708/10/09 42346 50 PROLAPSE P 10X6X3 P P BENIGN CYSTIC TERATOMA
53 G3710/10/09 81987 30 MASS P 15X8X6 P P BENIGN MUCINOUS CYSTADENOMA
54 G3754/10/09 42878 55 PAIN, MASS P 15X6X3 P P BENIGN MUCINOUS CYSTADENOMA
55 G3785/10/09 42049 45 MASS P 1‐16X10X4,2‐17X15X8  P p MUCINOUS TUMOR OF BORDERLINE MALIGNANCY
56 G3839/11/09 87014 19 PAIN, MASS P 10X5X3 P P BENIGN MUCINOUS CYSTADENOMA
57 G3858/11/09 89965 19 MASS P 9X6X1 P P BENIGN MUCINOUS CYSTADENOMA
58 G3861/11/09 18343 26 MASS P 13X6X3 P P BENIGN MUCINOUS CYSTADENOMA
59 G3863/11/09 87362 32 PAIN P 5X3X1 P P BENIGN SEROUS CYST
60 G3864/11/09 42937 32 MASS, PAIN P 6X5X2 P P BENIGN SEROUS CYSTADENOMA
61 G4021/11/09 42588 60 MASS P 8X6X3 P P SEROUS PAPILLARY CYSTADENOCARCINOMA
62 G4026/11/09 42711 45 PAIN, MASS P 5X4X2  P P BENIGN SEROUS PAPILLARY CYSTADENOMA
63 G4071/11/09 42601 65 MASS P 8X5X3 P P BENIGN PAPILLARY SEROUS CYSTADENOMA
64 G4088/11/09 43135 28 MASS P 10X5X3 P P BENIGN MUCINOUS CYSTADENOMA
65 G4117/11/09 42722 37 MASS, PAIN P 11X7X2 P P PAPILLARY SEROUS CYSTADENOCARCINOMA
66 G4190/111/09 90565 36 PAIN P 7X5X4 P P BENIGN MUCINOUS CYSTADENOMA
67 G4243/12/09 95878 60 PAIN P 6X3X1 P P BENIGN PAPILLARY SEROUS CYSTADENOMA
68 G4244/12/09 92151 23 MASS P 10X4X1 P P BENIGN SEROUS CYSTADENOMA
69 G4339/12/09 94915 17 MASS P 20X15X5 P P OMENTUM +,WELL DIFFERENTIATED SEROUS CYSTADENOCARCINOMA 
70 G4351/12/09 94661 35 PAIN P 2.5X2X1 P P OMENTUM PAPILLARY ADENOCARCINOMA 
71 G4352/12/09 91256 37 MASS, PAIN P 15X6X4 P P BENIGN SEROUS CYSTADENOMA
72 G4353/12/09 97007 27 PAIN P 6X4X2 P P BENIGN SEROUS CYSTADENOMA
73 G4374/12/09 42953 40 MENSTRUAL DISTURBANCES P 7X3X2 P P PAPILLAYR SEROUS CYSTADENOCARCINOMA 
74 G4431/12/09 88198 48 MASS P 18X10X4 P P CERVIX & ENDPOORLY DIFFERENTIATED CARCINOMA
75 G4444/12/09 207017 47 PAIN P 7X6X2 P p FIBROTHECOMA
76 G4450/12/09 95607 50 MASS P 8X6X3 P P PAPILLARY SEROUS CYSTADENOCARCINOMA
77 G44409/12/09 99869 63 PAIN P 3X2X1 P p MUCINOUS TUMOR OF BORDERLINE MALIGNANCY
78 G4509/12/09 43681 36 PAIN P 4X3X2  P P BENIGN PAPILLARY SEROUS CYSTADENOMA
79 G4603/12/09 73548 42 MENSTRUAL DISTURBANCE P 13X5X2 P P BENIGN SEROUS CYSTADENOMA
80 G4613/12/09 97878 65 MASS,menstrual disturbances P 22X15X6 P GRANULOSA CELL TUMOR  VIM +, INH+ 4.80%  Ia
81 G11/1/10 43778 60 PAIN P 5X3X1 P P BENIGN SEROUS CYSTADENOMA
82 G15/1/10 44024 35 MASS P 10X4X3 P P MUCINOUS CYSTADENOCARCINOMA  32.20%
83 G104/1/10 43933 42 ABDOMINAL DISTENSION  P 12X7X5 P P ASCITES+ PAPILLARY SEROUS CYSTADENOCARCINOMA 29%
84 G105/1/10 43629 45 ABDOMINAL DISTENSION  P 8X6X4 P P ASCITES+ SEROUS CYSTADENOCARCINOMA 29.20%
85 G142/2/10 107571 45 ABDOMINAL DISTENSION  P 5X4X2 P P BENIGN SEROUS CYSTADENOMA
86 G169/2/10 98490 48 PAIN P 10X8X3 P P PAPILLARY SEROUS CYSTADENOCARCINOMA
87 G173/2/10 36221 19 PAIN, MASS P 8X5X3 P P BENIGN  SEROUS CYSTADENOMA
88 G176/2/10 103285 53 PAIN P 5X3X1 P P BENIGN SEROUS CYSTADENOMA
89 G177/2/10 720 45 PAIN P 15X6X5 P P BENIGN MUCINOUS CYSTADENOMA
                    G232/2/10 44144 52 PAIN P 15X4X3 P p CARCINOID TUMOR INH ‐,CHR + 3.00%
91 G419/3/10 OOO490 46 PAIN P 13X6X4 P P BENIGN MUCINOUS CYSTADENOMA
92 G437/3/10 OO5O9 35 PAIN P 14X9X5 P P ASCITES+ ENDOMETRIOID TYPE OF ADENOCARCINOMA
93 G619/3/10 50569 35 PAIN P 3X2X1 P P BENIGN SEROUS CYSTADENOMA
94 G695/3/10 4534 49 MASS P 30X25X10 P P BENIGN MUCINOUS CYSTADENOMA
95 G698/3/10 10367 45 PAIN P 6X4X2 P P BENIGN MUCINOUS CYSTADENOMA
96 G727/3/10 1109 25 MASS, PAIN P 15X6X3 P P YOLK SAC TUMOR
97 G773/3/10 15119 40 ABDOMINAL DISTENSION  P 4X2.5X2 P P OMENTUM+,  ADEN OCARCINOMA
98 G774/3/10 715 36 PAIN P 4X3X2  P P ENDOMETRIOTIC CYST WITH BENIGN  MUCINOUS  CYSTADENOMA
99 G828/3/10 136011 27 PAIN P 7X4X2 P P BENIGN SEROUS CYST
100 G833/3/10 1345 30 PAIN P 6X4X2 P P BENIGN MUCINOUS CYSTADENOMA
101 G840/3/10 1462 49 ABDOMINAL DISTENSION  p 12x3x2 p p ASCITES+ MALIGNANT SEROUS CYSTADENOCARCINOMA
102 G884/3/10 1555 72 MASS P 15X5X3 P P BENIGN MUCINOUS CYSTADENOMA 
103 G912/4/10 15596 55 ABDOMINAL DISTENSION  P 4X3X2  P P OMENTUM+, MALIGNANT PAPILLARY SEROUS CYSTADENOCARCINOMA
104 G990/4/10 1858 35 MASS, MENSTRUAL DISTURBANCP 5X4X2.5 P P B/L BENIGN MUCINOUS CYSTADENOMA
105 G1040/4/10 1744 60 PAIN P 7X3X2 P P BENIGN SEROUS CYSTADENOMA
106 G1042/4/10 1942 20 MASS, PAIN P 12X5X3 P P BENIGN MUCINOUS CYSTADENOMA
107 G829/4/10 1956 28 MASS P 10X4X2 P P BENIGN MUCINOUS CYSTADENOMA
108 G1060/4/10 207197 22 PAIN, MASS P 10X6X3 P P BENIGN CYSTIC TERATOMA
109 G1133/4/10 15594 42 MASS P 14X6X3 P P BENIGN MUCINOUS CYSTADENOMA
110 G1134/4/10 1656 32 PAIN, MASS P 20X11X4 P P ascites+ SEROUS PAPILLARY ADENOCARCINOMA
111 G1226/4/10 1740 39 MASS P 11X4X2 P P BENIGN SEROUS CYSTADENOMA
112 G1227/4/10 2156 30 PAIN P 4X3X2  P P BENIGN SEROUS CYST
113 G1229/4/10 2569 28 PAIN P 12X5X3 P P BENIGN CYSTIC TERATOMA
114 G1276/5/10 24718 16 PAIN P 12X3X2 P P BENIGN CYSTIC TERATOMA
115 G1286/5/10 2495 52 MASS P 8.5X5X1.5 P P BENIGN MUCINOUS CYSTADENOMA
116 G1365/5/10 28611 40 MASS, PAIN P 4X2.5X2 P P ascites+ PAPILLARY SEROUS CYSTADENOCARCINOMA OVARY
117 G1447/5/10 3684 30 MASS P 3,5X2.5X2 P P BENIGN SEROUS CYSTADENOMA
118 G1459/5/10 30514 55 PAIN P 4X3X2  P P PAPILLARY ADENOCARCINOMA 
119 G1491/5/10 4149 50 MASS P 30X25X8 P P BENIGN MUCINOUS CYSTADENOMA
120 G1571/5/10 4610 25 PAIN P 10X5X2 P P BENIGN SEROUS CYSTADENOMA
121 G1644/5/10 3369 41 MASS, PAIN P 8X5X3 P P ADENOCARCINOMA
122 G1646/5/10 3158 37 MASS, PAIN P 5X4X3 p p BENIGN SEROUS CYSTADENOMA
123 G1673/6/10 3134 39 MASS, PAIN P 5X3X2 P P ascites+ PAPILLARY SEROUS ADENOCARCINOMA 
124 G1730/6/10 36369 42 MASS P 11X5X2 P P BORDERLINE SEROUS TUMOR
125 G1731/6/10 3504 61 MASS P 1‐16X5X3,,2‐8X5X3 P P(both) P(both)  ASCITES + 1. BENIGN MUCINOUS CYSTADENOMA, 2.MUCINOUS CYSTADENOCARCINOMA 32.60%
126 G1856/6/10 3814 40 MASS, PAIN P 5X3X2 P P BENIGN SEROUS CYSTADENOMA
127 G1857/6/10 37644 19 MENSTRUAL DISTURBANCES P 10X6X4 P p POORLY DIFFERENTIATED SEROUS  CARCINOMA INH ‐, EMA + 25.10%
128 G1879/6/10 5445 40 MASS P 11X9X4 P p ADULT GRANULOSA CELL TUMOR VIM +, INH+ 4.40%  Ia
129 G1888/6/10 3662 23 MASS P 15X13X7 P p ADULT GRANULOSA CELL TUMOR VIM +, INH+ 7.90%  Ic
130 G1891/6/10 3673 50 mass ABDOMEN P 4X2X1 P P KRUKENBERG TUMOR
131 G1912/6/10 41477 59 MASS  P 8X5X3 P P OMENTUM + SEROUS CYSTADENOCARCINOMA
132 G1920/6/10 41791 32 PAIN P 3X2X1 P P DYSGERMINOMA 25.30%
133 G 1940/6/10 O4119 45 MASS P 4x4x3 p
134 G2016/7/10 41498 12 MASS P 13X10X5 P P IMMATURE TERATOMA GARDE 11
135 G2032/7/10 2925 27 PAIN P 6X2X2 P P DERMOID CYST
136 G2040/7/10 3835 51 MASS P 5x3x2 P OMENTUM+ METASTATIC DEPOSITS
137 G2059/7/10 40560 35 MASS P 14X5X5 P P BENIGN MUCINOUS CYSTADENOMA
138 G2062/7/10 7403 30 PAIN P 6X3X3 P P BENIGN SEROUS CYSTADENOMA 2.60%
139 G2064/7/10 44158 30 PAIN P 6X2X2 P P BENIGN SEROUS CYSTADENOMA
140 G2O81/7/10 4081 27 MASS P 14X6X6 P P BENIGN MATURE TERATOMA
141 G2083/7/10 43121 30 PAIN P 6X4X2 P P ENDOMETRIOTIC CYST
142 G2085/7/10 42476 40 MASS P 17X10X8 P FIBROMA
143 G2114/7/10 4571 26 PAIN P 8X5X5 P P BENIGN PAPPILARY SEROUS CYSTADENOMA
144 G2218/7/10 4752 40 PAIN P 3X2X2 P P B/L BENIGN SEROUS CYSTADENOMA
145 G2275/7/10 46094 60 PAIN P 5x3x3 p p BENIGN SEROUS CYSTADENOMA
146 G2299/7/10 42116 34 MASS, PAIN P 9X6X4 P P BENIGN SEROUS CYSTADENOMA
147 G2316/7/10 52171 23 PAIN P 5X3X3 P P BENIGN CYSTIC TERATOMA
148 G23338/7/10 51181 45 PAIN P 8X5X5, P P(both) p(both CYSTIC TERATOMA WITH ADENOCARCINOMA
149 G2394/8/10 40618 28 PAIN P 5X3X3 P P BENIGN MUCINOUS CYST
150 G2437/78/10 43214 48 MASS, PAIN P 10X7X5 P P ASCITES+ PAPPILARY CYSTADENOCARCINOMA
151 G2493/8/10 46144 40 PAIN P 9X7X3.5 P P BENIGN SEROUS CYSTADENOMA
152 G2499/8/10 30619 42 PAIN P 2X2X1 P P BENIGN SEROUS CYSTADENOMA
153 G2502/8/10 52116 35 PAIN P 15X4X6 P P BENIGN SEROUS CYSTADENOMA
154 G2556/8/10 54061 47 PAIN P 3X2X1 P P SEROUS PAPPILARY CYSTADENOMA OF BORDERLINE MALIGNANCY 8.30%
155 G2605/8/10 53216 65 MASS P 10X6X2 P P SIMPLE SEROUS CYST
156 G2652/8/10 55416 17 MENSTRUAL DISTURBANCES P 9X5X5 P p GRANULOSA CELL TUMOR  VIM + ,INH + 2.80%  Ia
157 G2703/8/10 45326 50 PAIN P 4X2X1, P P ASCITES+ SEROUS ADENOCARCINOMA
158 G2831/9/10 44613 60 MASS P 7X3.5X1 P P BENIGN SEROUS CYSTADENOMA
159 G2928/9/10 43216 55 PAIN P 8X3.5X1 P P BENIGN SEROUS CYST
160 G2930/9/10 52164 60 MASS P 9X5X3 P P asites+ MUCINOUS CYSTADENOCARCINOMA
161 G2936/9/10 43144 12 PAIN P 3X2X2 P P BENIGN CYSTIC TERATOMA
162 G2951/9/10 4861 50 MASS P 9X5X3 P P BENIGN SEROUS CYSTADENOMA
163 G3044/10/10 4321 45 MASS, PAIN P 8X6X3 P P BENIGN SEROUS CYSTADENOMA
164 G3045/8/10 5628 28 MASS P 10X5X6 P P ASCITES+ PAPPILARY CYSTADENOCARCINOMA
165 G3120/10/10 5698 48 PAIN P 4X3X2 P P PAPPILARY MUCINOUS CYSTADENOCARCINOMA
166 G3169/10/10 1123 28 MASS P 7X5X2, P p GRANULOSA CELL TUMOR VIM +, INH+ 3.40%  Ia
167 G3171/10/10 6754 45 PAIN P 8X6X2 P P ascites+ PAPPILARY SEROUS CYSTADENOCARCINOMA
168 G3173/10/10 5656 15 MASS, PAIN P 16X7X4 P p ASCITES+ YOLK SAC TUMOR 31.30%
169 G3228/10/10 8767 30 MASS P 12X9X5 P P BENIGN SEROUS CYSTADENOMA
170 G3253/10/10 9876 70 MASS P 7X5X2 P P BBENIGN MUCINOUS CYSTADENOMA
171 G3076/10/10 4567 58 PAIN P 13X6X4 P P BENIGN MUCINOUS CYSTADENOMA
172 G3277/10/10 4324 30 PAIN P 7X4X3 P P ASCITES+,OM PAPILLARY SEROUS ADENOCARCINOMA
173 G3406/11/10 7656 38 PAIN P 6X5X2 P P BENIGN MUCINOUS CYST
174 G3407/11/10 5463 45 PAIN P 4X3X2 P P BENIGN CYSTIC TERATOMA
175 G3433/11/10 6545 42 MASS, PAIN P 3X5X2 P P BENIGN SEROUS CYSTADENOMA 3%
176 G3535/11/10 5643 20 MASS P 13X10X9 P P DYSGERMINOMA
177 G3577/11/10 5674 49 MASS P 18X12X6 P P BENIGN MUCINOUS CYSTADENOMA 3.10%
178 G3657/11/10 3421 35 MASS P 4X3X2 P p KRUKENBERG TUMOR
179 G3680/12/10 5645 39 PAIN P 10X5X2 P P MUCINOUS TUMOR OF BORDERLINE MALIGNANCY 6.20%
180 G3694/12/10 4567 40 PAIN P 5X3X2 P P BENIGN  MUCINOUS CYSTADENOMA
181 G3695/12/10 4567 43 MASS P 5X3X2 P P PAPILLARY MUCINOUS CYSTADENOCARCINOMA
182 G3696/12/10 4545 16 MASS P 10X5X4 P P YOLK SAC TUMOR
183 G3792/12/10 3654 38 MASS, PAIN P 16X6X4 P P ASCITES+, OMPAPILLARY SEROUS CYSTADENO CARCINOMA 
184 G3793/12/10 3456 47 PAIN P 4X3X2 P P PAPILLARY ADENOCARCINOMA OVARY
185 G3861/12/10 3455 65 PAIN P 4X2X1 P P BENIGN MUCINOUS CYSTADENOMA 3%
186 G3880/12/10 4567 43 PAIN P 3X2X1 P P OMENTUM= adenocarcinoma 
187 G3928/12/10 6745 2 PAIN,mass, precocious puberty p 4x3x2 p p juvenile granulosa cell tumor VIM +, INH+ 4.20%  Ia
188 G 4079/12/10 22567 65 MASS P 17X7X4 P P BORDERLINE MUCINOUS CYSTADENOMA 6%
189 G4158/1/11 4534 70 PAIN P 8X4X2 P P MUCINOUS TUMOR OF BORDERLINE MALIGNANCY
190 G4175/1/11 2234 53 MASS P 8X5X2 P P BENIGN MUCINOUS  CYSTADENOMA WITH BRENNER TUMOR
191 G45/1/11 3324 45 PAIN P 7X5X3 P P ENDOMETRIOID CARCINOMA OVARY
192 G58/1/11 4534 40 PAIN P 8X4X2 P P OMENTUM + papillary adenocarcinoma
193 G60/1/11 10110 43 MASS P 14X12X5 P P OMENTUM + PAPILLARY SEROUS ADENOCARCINOMA
194 G269/2/11 3122 29 MASS, PAIN P 8X5X2 P P B/L KRUKENBERG TUMOR
195 G476/2/11 8234 65 PAIN P 6X3X2, 2x1x0.5 P P B/L MALIGNANT BRENNER TUMOR
196 G695/3/11 1525 62 PAIN P 5X4X3 P P(both)  P(both)  1.PAPILLARY ADENOCARCINOMA, 2. SEROUS CYSTADENOMA
197 G762/12/11 1618 55 PAIN, MENSTRUAL DISTURBANCEP 6X4X2 P p GRANULOSA CELL TUMOR VIM +, INH+ 8.40%  Ic
198 G934/3/11 2803 37 PAIN P 3X2X2,  P P B/L PAPILLARY MUCINOUS CYSTADENOMA OF BORDERLINE MALIGNANCY 6.10%
199 G1089/3/11 17758 36 MASS, PAIN P 9X7X4 P P BENIGN CYSTIC TERATOMA
200 G1137/3/11 ESI‐11179009 56 PAIN P 4X3X2 P p FIBROMA
